View Filing Data

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Dec. 31, 2012	Feb. 28, 2013	Jun. 30, 2012
Document and Entity Information [Abstract]
Entity Registrant Name	Emergent BioSolutions Inc.
Entity Central Index Key	0001367644
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 367
Entity Common Stock, Shares Outstanding		35,925,891
Document Fiscal Year Focus	2012
Document Fiscal Period Focus	FY
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2012

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Current assets:
Cash and cash equivalents	$ 141,666	$ 143,901
Investments	0	1,966
Accounts receivable	96,043	74,153
Inventories	15,161	14,661
Deferred tax assets, net	1,264	1,735
Income tax receivable, net	0	9,506
Restricted cash	0	220
Prepaid expenses and other current assets	9,213	8,276
Total current assets	263,347	254,418
Property, plant and equipment, net	241,764	208,973
In-process research and development	41,800	51,400
Goodwill	5,502	5,502
Assets held for sale	0	11,765
Deferred tax assets, net	11,087	13,999
Other assets	730	807
Total assets	564,230	546,864
Current liabilities:
Accounts payable	31,297	40,530
Accrued expenses and other current liabilities	1,488	1,170
Accrued compensation	22,726	20,884
Contingent value rights, current portion	0	1,748
Taxes Payable, Current, Total	115	0
Long-term indebtedness, current portion	4,470	5,360
Deferred revenue, current portion	1,811	1,362
Total current liabilities	61,907	71,054
Contingent value rights, net of current portion	0	3,005
Long-term indebtedness, net of current portion	58,304	54,094
Other liabilities	1,891	1,984
Total liabilities	122,102	130,137
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 15,000,000 shares authorized, 0 shares issued and outstanding at December 31, 2012 and December 31, 2011, respectively	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized, 36,272,550 shares issued and 35,869,392 shares outstanding at December 31, 2012; 36,002,698 shares issued and outstanding at December 31, 2011	36	36
Additional paid-in capital	230,964	220,654
Treasury stock, at cost, 403,158 and 0 common shares at December 31, 2012 and 2011, respectively	(5,906)	0
Accumulated other comprehensive loss	(4,129)	(3,313)
Retained earnings	220,393	196,869
Total Emergent BioSolutions Inc. stockholders' equity	441,358	414,246
Noncontrolling interest in subsidiaries	770	2,481
Total stockholders' equity	442,128	416,727
Total liabilities and stockholders' equity	$ 564,230	$ 546,864

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2012	Dec. 31, 2011
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	36,272,550	36,002,698
Common stock, shares outstanding (in shares)	35,869,392	36,002,698
Treasury Stock ( in Shares)	403,158	0

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenues:
Product sales	$ 215,879	$ 202,409	$ 251,381
Contracts and grants	66,009	70,975	34,790
Total revenues	281,888	273,384	286,171
Operating expenses:
Cost of product sales	46,077	42,171	47,114
Research and development	120,226	124,832	89,295
Selling, general and administrative	76,018	74,282	76,205
Impairment of in-process research and development	9,600	0	0
Income from operations	29,967	32,099	73,557
Other income (expense):
Interest income	134	105	832
Interest expense	(6)	0	0
Other income (expense), net	1,970	(261)	(1,023)
Total other income (expense)	2,098	(156)	(191)
Income before provision for income taxes	32,065	31,943	73,366
Provision for income taxes	13,922	15,830	26,182
Net income	18,143	16,113	47,184
Net loss attributable to noncontrolling interest	5,381	6,906	4,514
Net income attributable to Emergent BioSolutions Inc.	$ 23,524	$ 23,019	$ 51,698
Earnings per share - basic (in dollars per share)	$ 0.65	$ 0.65	$ 1.63
Earnings per share - diluted (in dollars per share)	$ 0.65	$ 0.64	$ 1.59
Weighted-average number of shares - basic (in shares)	36,080,495	35,658,907	31,782,286
Weighted-average number of shares - diluted (in shares)	36,420,662	36,206,052	32,539,500

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Consolidated Statements of Comprehensive Income [Abstract]
Net income attributable to Emergent BioSolutions Inc.	$ 23,524	$ 23,019	$ 51,698
Foreign currency translations, net of tax	(816)	(1,203)	(634)
Comprehensive income	$ 22,708	$ 21,816	$ 51,064

- Definition

The change in equity [net assets] of a business enterprise during a period from transactions and other events and circumstances from non-owner sources which are attributable to the economic entity, including both controlling (parent) and noncontrolling interests. It includes all changes in equity during a period except those resulting from investments by owners and distributions to owners, including any and all transactions which are directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Net Income
-URI http://asc.fasb.org/extlink&oid=6518256

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6943989&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.18)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.22)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Other Comprehensive Income
-URI http://asc.fasb.org/extlink&oid=6519514

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=20435746&loc=d3e565-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 130
-Paragraph 10, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph A7
-Appendix A

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 87-21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 19
-Article 5

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 51
-Paragraph 38
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 95
-Paragraph 28, 29, 30
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 20
-Article 9

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Cash flows from operating activities:
Net income	$ 18,143	$ 16,113	$ 47,184
Adjustments to reconcile to net cash provided by operating activities:
Stock-based compensation expense	11,115	10,739	7,063
Depreciation and amortization	11,197	9,355	5,990
Deferred income taxes	3,383	20,188	9,229
Non-cash development expenses from joint venture	3,670	5,290	5,995
Impairment of in-process research and development	9,600	0	0
Impairment of long-lived assets	0	976	1,218
Change in fair value of contingent value rights	(3,005)	221	0
Provision for impairment of accrued interest on note receivable	0	0	1,032
Excess tax benefits from stock-based compensation	(1,588)	(4,608)	(2,609)
Other	(40)	392	(38)
Changes in operating assets and liabilities:
Accounts receivable	(21,890)	(34,873)	19,094
Inventories	(500)	(1,939)	799
Income taxes	8,055	1,422	(4,454)
Prepaid expenses and other assets	(1,038)	660	(764)
Accounts payable	274	2,510	3,392
Accrued expenses and other liabilities	169	(95)	(447)
Accrued compensation	1,649	(3,303)	6,175
Deferred revenue	449	(10,863)	(838)
Net cash provided by operating activities	39,643	12,185	98,021
Cash flows from investing activities:
Purchases of property, plant and equipment	(53,845)	(54,026)	(22,101)
Proceeds from sale of assets	11,765	0	0
Proceeds from maturity of investments	1,966	4,250	6,518
Purchase of investments	0	(4,187)	0
Acquisition of Trubion Pharmaceuticals, Inc., net of cash acquired	0	0	(17,873)
Repayment of note receivable	0	0	10,000
Net cash used in investing activities	(40,114)	(53,963)	(23,456)
Cash flows from financing activities:
Proceeds from borrowings on long-term indebtedness	13,547	27,522	15,000
Issuance of common stock subject to exercise of stock options	761	10,026	7,235
Excess tax benefits from stock-based compensation	1,588	4,608	2,609
Principal payments on long-term indebtedness and line of credit	(10,227)	(15,494)	(33,291)
Contingent value right payment	(1,748)	(10,000)	0
Purchase of treasury stock	(5,906)	0	0
Restricted cash deposit	220	(3)	(2)
Net cash provided by (used in) financing activities	(1,765)	16,659	(8,449)
Effect of exchange rate changes on cash and cash equivalents	1	1	(21)
Net increase (decrease) in cash and cash equivalents	(2,235)	(25,118)	66,095
Cash and cash equivalents at beginning of year	143,901	169,019	102,924
Cash and cash equivalents at end of year	141,666	143,901	169,019
Supplemental disclosure of cash flow information:
Cash paid during the year for interest	2,137	1,740	2,176
Cash paid during the year for income taxes	6,537	4,280	22,440
Supplemental information on non-cash investing and financing activities:
Issuance of common stock to acquire Trubion Pharmaceuticals, Inc.	0	0	61,203
Purchases of property, plant and equipment unpaid at year end	$ 5,612	$ 15,509	$ 3,519

Consolidated Statement of Changes in Stockholders' Equity - USD ($) $ in Thousands	$0.001 Par Value Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Accumulated Other Comprehensive Loss [Member]	Noncontrolling Interest in Subsidiary [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2009	$ 31	$ 120,492	$ 0	$ (1,476,000)	$ 2,616	$ 122,152	$ 243,815
Balance (in shares) at Dec. 31, 2009	30,831,360
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock for the Trubion Pharmaceuticals, Inc. acquisition	$ 3	61,200	0	0	0	0	61,203
Issuance of stock for the Trubion Pharmaceuticals, Inc. acquisition (in shares)	3,351,817
Employee equity award plans activity	$ 1	15,997	0	0	0	0	15,998
Employee equity award plans activity (in shares)	828,246
Non-cash development expenses from joint venture	$ 0	0	0	0	5,995	0	5,995
Net loss attributable to noncontrolling interest	0	0	0	0	(4,514)	0	(4,514)
Net income	0	0	0	0	0	51,698	51,698
Foreign currency translations, net of tax	0	0	0	(634,000)	0	0	(634)
Balance at Dec. 31, 2010	$ 35	197,689	0	(2,110,000)	4,097	173,850	373,561
Balance (in shares) at Dec. 31, 2010	35,011,423
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity award plans activity	$ 1	22,965	0	0	0	0	22,966
Employee equity award plans activity (in shares)	991,275
Non-cash development expenses from joint venture	$ 0	0	0	0	5,290	0	5,290
Net loss attributable to noncontrolling interest	0	0	0	0	(6,906)	0	(6,906)
Net income	0	0	0	0	0	23,019	23,019
Foreign currency translations, net of tax	0	0	0	(1,203,000)	0	0	(1,203)
Balance at Dec. 31, 2011	$ 36	220,654	0	(3,313,000)	2,481	196,869	$ 416,727
Balance (in shares) at Dec. 31, 2011	36,002,698						36,002,698
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Employee equity award plans activity	$ 0	10,310		0	0	0	$ 10,310
Employee equity award plans activity (in shares)	269,852
Non-cash development expenses from joint venture	$ 0	0	0	0	3,670	0	3,670
Stock Repurchased During Period, Value			$ (5,906)				(5,906)
Stock repurchased during period (in shares)			(403,158)
Net loss attributable to noncontrolling interest	0	0	$ 0	0	(5,381)	0	(5,381)
Net income	0	0	0	0	0	23,524	23,524
Foreign currency translations, net of tax	0	0	0	(816,000)	0	0	(816)
Balance at Dec. 31, 2012	$ 36	$ 230,964	$ (5,906)	$ (4,129,000)	$ 770	$ 220,393	$ 442,128
Balance (in shares) at Dec. 31, 2012	36,272,550						35,869,392

Nature of the business and organization	12 Months Ended
Nature of the business and organization	Dec. 31, 2012
Nature of the business and organization [Abstract]
Nature of the business and organization	1. Nature of the business and organization Emergent BioSolutions Inc. (the "Company" or "Emergent") is a specialty pharmaceutical company seeking to protect and enhance life by developing and offering specialized products to healthcare providers and governments for use in addressing medical needs and emerging health threats. The Company is developing products to be offered both to biodefense and commercial markets. The Company commenced operations as BioPort Corporation ("BioPort") in September 1998 through an acquisition from the Michigan Biologic Products Institute of rights to the marketed product, BioThrax, vaccine manufacturing facilities at a multi-building campus on approximately 12.5 acres in Lansing, Michigan and vaccine development and production know-how. In December 2001, the U.S. Food and Drug Administration ("FDA") approved a supplement to the Company's manufacturing facility license for the manufacture of BioThrax at the renovated facilities. In June 2004, the Company completed a corporate reorganization ("Reorganization"). As a result of the Reorganization, BioPort became a wholly owned subsidiary of the Company. The Company subsequently renamed and converted this subsidiary to Emergent Biodefense Operations Lansing LLC ("Emergent Biodefense Operations"). The Company acquired a portion of its portfolio of vaccine and therapeutic product candidates through an acquisition of Microscience Limited ("Microscience") in a share exchange in June 2005, and acquisitions of substantially all of the assets, for cash, of Antex Biologics Inc. ("Antex") in May 2003 and ViVacs GmbH, Germany ("ViVacs") in July 2006. The Company renamed Microscience as Emergent Product Development UK Limited. The assets acquired from Antex are held in an entity incorporated as Emergent Product Development Gaithersburg Inc., and the assets acquired from ViVacs are held in an entity incorporated as Emergent Product Development Germany GmbH. On October 28, 2010, the Company acquired Trubion Pharmaceuticals, Inc. ("Trubion") for cash, equity and contingent value rights. Concurrent with the acquisition, the Company converted Trubion to Emergent Product Development Seattle, LLC.

Summary of significant accounting policies

12 Months Ended

Dec. 31, 2012

Summary of significant accounting policies [Abstract]

Summary of significant accounting policies

2. Summary of significant accounting policies

Basis of presentation and consolidation

The accompanying consolidated financial statements include the accounts of Emergent and its wholly-owned and majority-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation. For investments in variable interest entities, the Company consolidates when it is determined to be the primary beneficiary.

Use of estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

Cash and cash equivalents

Cash equivalents are highly liquid investments with a maturity of 90 days or less at the date of purchase and consist of time deposits and investments in money market funds with commercial banks and financial institutions. Also, the Company maintains cash balances with financial institutions in excess of insured limits. The Company does not anticipate any losses with such cash balances.

Investments

Investments that are classified as available-for-sale are measured at fair value in the balance sheets, and unrealized holding gains and losses on investments are reported as a separate component of stockholder equity until realized. Realized gains and losses are reported in other income (expense), net, on a specific identification basis.

For debt securities, if the Company intends to either sell or determines that it will more likely than not be required to sell a debt security before recovery of the entire amortized cost basis or maturity of the debt security, the Company recognizes the entire impairment in earnings. If the Company does not intend to sell the debt security but determines that it will not be more likely than not required to sell the debt security and it does not expect to recover the entire amortized cost basis, the impairment is bifurcated into the amount attributed to the credit loss, which is recognized in earnings, and all other causes, which are recognized in other comprehensive income. Regardless of the Company's intent to sell a security, it performs additional analysis on all securities with unrealized losses to evaluate losses associated with the creditworthiness of the security. Credit losses are identified when the Company does not expect to receive cash flows sufficient to recover the amortized cost basis of a security.

Fair value of measurements

The Company measures and records cash equivalents and investment securities considered available-for-sale at fair value in the accompanying financial statements. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability, an exit price, in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The three-tier fair value hierarchy, which prioritizes the inputs used in measuring fair value include:

Level 1 — Observable inputs for identical assets or liabilities such as quoted prices in active markets;

Level 2 — Inputs other than quoted prices in active markets that are either directly or indirectly observable; and

Level 3 — Unobservable inputs in which little or no market data exists, which are therefore developed by the Company using estimates and assumptions that reflect those that a market participant would use.

The fair value of U.S. Treasury securities (Level 2) is obtained from an independent pricing service and is based on recent sales of similar securities and other observable market data.

The carrying amounts of the Company's short-term financial instruments, which include cash and cash equivalents, accounts receivable and accounts payable, approximate their fair values due to their short maturities. The fair value of the Company's long-term indebtedness is estimated based on the quoted prices for the same or similar issues or on the current rates offered to the Company for debt of the same remaining maturities.

Restricted cash

Restricted cash at December 31, 2011 includes a certificate of deposit held by a bank as collateral for a letter of credit acting as a security deposit on a loan. As of December 31, 2011 the Company had restricted cash of $220,000. The Company had no restricted cash as of December 31, 2012.

Significant customers and accounts receivable

For the years ended December 31, 2012, 2011 and 2010, the Company's primary customer was the U.S. Department of Health and Human Services ("HHS"). For the years ended December 31, 2012, 2011 and 2010, revenues from HHS and HHS agencies comprised 97.9%, 91.3% and 97.5%, respectively, of total revenues and are included in the Company's Biodefense segment. As of December 31, 2012 and 2011, the Company's receivable balances were comprised of 99.9% and 90.0%, respectively, from this customer. Unbilled accounts receivable, included in accounts receivable, totaling $19.9 million and $19.0 million as of December 31, 2012 and 2011, respectively, relate to various service contracts for which work has been performed, though invoicing has not yet occurred. Substantially all of the unbilled receivables are expected to be billed and collected within the next 12 months. Accounts receivable are stated at invoice amounts and consist primarily of amounts due from the U.S. government and collaborative partners as well as amounts due under reimbursement contracts with other government entities and non-government and philanthropic organizations. If necessary, the Company records a provision for doubtful receivables to allow for any amounts which may be unrecoverable. This provision is based upon an analysis of the Company's prior collection experience, customer creditworthiness and current economic trends. As of December 31, 2012 and 2011, an allowance for doubtful accounts was not recorded as the collection history from the Company's customers indicated that collection was probable.

Concentrations of credit risk

Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and investments and accounts receivable. The Company places its cash and cash equivalents and investments with high quality financial institutions. Management believes that the financial risks associated with its cash and cash equivalents and investments are minimal. Because accounts receivable consist primarily of amounts due from the U.S. government for product sales and from government agencies under government grants and development contracts, management deems there to be minimal credit risk.

Inventories

Inventories are stated at the lower of cost or market, with cost being determined using a standard cost method, which approximates average cost. Average cost consists primarily of material, labor and manufacturing overhead expenses and includes the services and products of third party suppliers. The Company analyzes its inventory levels quarterly and writes down, in the applicable period, inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected customer demand. The Company also writes off in the applicable period the costs related to expired inventory.

Property, plant and equipment

Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:

Buildings	31-39 years
Building improvements	10-39 years
Furniture and equipment	3-15 years
Software	Lesser of 3-5 years or product life
Leasehold improvements	Lesser of the asset life or lease term

Upon retirement or sale, the cost of assets disposed of and the related accumulated depreciation are removed from the accounts and any resulting gain or loss is credited or charged to operations. Repairs and maintenance costs are expensed as incurred.

Income taxes

Income taxes are accounted for using the liability method. Deferred tax assets and liabilities are recognized for future tax consequences attributable to differences between financial statement carrying amounts of existing assets and liabilities and their respective tax bases and net operating loss and research and development tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the year in which those temporary differences are expected to be recovered or settled.

The Company's ability to realize deferred tax assets depends upon future taxable income as well as the limitations discussed below. For financial reporting purposes, a deferred tax asset must be reduced by a valuation allowance if it is more likely than not that some portion or all of the deferred tax assets will not be realized prior to expiration. The Company considers future taxable income and ongoing tax planning strategies in assessing the need for valuation allowances. In general, if the Company determines that it is more likely than not to realize more than the recorded amounts of net deferred tax assets in the future, the Company will reverse all or a portion of the valuation allowance established against its deferred tax assets, resulting in a decrease to the provision for income taxes in the period in which the determination is made. Likewise, if the Company determines that it is not more likely than not to realize all or part of the net deferred tax asset in the future, the Company will establish a valuation allowance against deferred tax assets, with an offsetting increase to the provision for income taxes, in the period in which the determination is made.

Under sections 382 and 383 of the Internal Revenue Code, if an ownership change occurs with respect to a "loss corporation", as defined, there are annual limitations on the amount of net operating losses and deductions that are available. The Company believes the use of net operating losses and research and development tax credits acquired in the Trubion acquisition will not be significantly limited. Due to the acquisition of Microscience in 2005 and the Company's initial public offering, the Company believes the use of the operating losses incurred prior to 2005 will be significantly limited.

Revenue recognition

The Company recognizes revenues from product sales if four basic criteria have been met:

§	there is persuasive evidence of an arrangement;

§	delivery has occurred or title has passed to the Company's customer;

§	the fee is fixed or determinable; and

§	collectability is reasonably assured.

All revenues from product sales are recorded net of applicable allowances for sales returns, rebates, special promotional programs, and discounts. For arrangements where the risk of loss has not passed to the customer, the Company defers the recognition of revenue until such time that risk of loss has passed to the customer. Also, the cost of revenue associated with amounts recorded as deferred revenue is recorded in inventory until such time as risk of loss has passed to the customer.

Under previous contracts with HHS, the Company invoiced HHS and recognized the related revenues upon delivery of the product to the government carrier, at which time title to the product passed to HHS. Effective September 30, 2011, the Company has a contract from the Centers for Disease Control and Prevention ("CDC"), an operating division of HHS, to supply up to 44.75 million doses of BioThrax over a five year period. Under the Company's contract from the CDC, the Company invoices the CDC and recognizes the related revenue upon acceptance by the government at delivery site, at which time title to the product passes the CDC.

Collaborative research and development agreements can provide for one or more of upfront license fees, research payments, and milestone payments. Agreements with multiple components ("deliverables" or "items") are evaluated to determine if the deliverables can be divided into more than one unit of accounting. An item can generally be considered a separate unit of accounting if both of the following criteria are met: (1) the delivered item(s) has value to the customer on a stand-alone basis; (2) if the arrangement includes a general right of return relative to the delivered item(s), delivery or performance of the undelivered item(s) is considered probable and substantially in control of the Company. Items that cannot be divided into separate units are combined with other units of accounting, as appropriate. Consideration received is allocated among the separate units based on the relative selling price of each deliverable. The Company deems service to have been rendered if no continuing obligation exists on the part of the Company.

Revenue associated with non-refundable upfront license fees under arrangements where the license fees and research and development activities cannot be accounted for as separate units of accounting is deferred and recognized as revenue either on a straight-line basis over the Company's continued involvement in the research and development process or based on the proportional performance of the Company's expected future obligation under the contract. Revenues from the achievement of research and development milestones, if deemed substantive, are recognized as revenue when the milestones are achieved, and the milestone payments are due and collectible. If not deemed substantive, the Company would recognize such milestone as revenue on a straight-line basis over the remaining expected term of continued involvement in the research and development process.

Milestones are considered substantive if all of the following conditions are met; (1) the milestone is non-refundable; (2) achievement of the milestone was not reasonably assured at the inception of the arrangement; (3) substantive effort is involved to achieve the milestone; and (4) the amount of the milestone appears reasonable in relation to the effort expended. Payments received in advance of work performed are recorded as deferred revenue.

The Company generates contract and grant revenue from cost-plus-fee contracts. Revenues on reimbursable contracts are recognized as costs are incurred, generally based on allowable costs incurred during the period, plus any recognizable earned fee. The Company considers fixed fees under cost-plus-fee contracts to be earned in proportion to the allowable costs incurred in performance of the contract. The Company analyzes cost for contracts and reimbursable grants to ensure reporting of revenues gross versus net is appropriate. For each of the three years in the period ended December 31, 2012, the costs incurred under the contracts and grants approximated the revenue earned.

The Company previously generated revenues from its agreements with Pfizer, Inc. ("Pfizer") and Abbott Laboratories ("Abbott"). Certain internal and external research and development costs and patent costs were reimbursed in connection with the Company's agreements. Reimbursed costs under the Pfizer agreement, which was terminated in September 2012, were recognized as revenue in the period in which the costs were incurred. Under the Company's agreement with Abbott, which was terminated in March 2012, Abbott shared development and clinical costs equally with the Company. Under the collaboration agreement, each of the Company and Abbott were required to report to the other party the total costs incurred for development. The total spending by each party was then compared to the spending by to the other party. In the event that the Company's spending for a given quarter exceeded the spending of Abbott, the Company recorded a net receivable in its financial statements equal to the difference between the Company's spending and 50% of the total spending for the period, and recognized revenue in this amount. If Abbott's spending for the quarterly period exceeded the Company's spending, the Company recorded a net payable in its financial statements equal to the difference between the Company's spending and 50% of the total spending, and recorded additional research and development expenses in this amount.

Contingent value rights

The Company records contingent value right ("CVR") obligations at fair value. Obligations generally become due and payable only upon achievement of certain developmental, regulatory or commercial milestones. The fair value model used for the CVR obligations are based on a discounted cash flow model that has been risk adjusted based on the probability of achievement of the milestones.

The Company believes that the inputs it uses for determining the fair value of the CVR obligations are Level 3 fair value measurements. The Company re-evaluates the fair value on a quarterly basis. Changes in the fair value of the CVR obligations can result from adjustments to the discount rates, updates in the assumed timing of achievement of any development milestones or changes in the probability of certain events and changes in the assumed probability associated with approval. Any future increase in the fair value of the CVR obligations, based on an increased likelihood that the underlying milestones will be achieved and the associated payment or payments will therefore become due and payable, will result in a charge to research and development expense in the period in which the increase is determined. Similarly, any future decrease in the fair value of the CVR obligations will result in a reduction in research and development expense.

Acquired in process research and development

Acquired in-process research and development ("IPR&D") represents the fair value assigned to research and development assets that the Company acquires that have not been completed at the date of acquisition. The value assigned to acquired IPR&D is determined by estimating the costs to develop the acquired technology into commercially viable products, estimating the resulting revenue from the projects, and discounting the net cash flows to present value. The revenue and cost projections used to value acquired IPR&D are, as applicable, reduced based on the probability of developing a new drug. Additionally, the projections considered the relevant market sizes and growth factors, expected trends in technology, and the nature and expected timing of new product introductions by us and our competitors. The resulting net cash flows from such projects are based on management's estimates of cost of sales, operating expenses, and income taxes from such projects. The rates utilized to discount the net cash flows to their present value are commensurate with the stage of development of the projects and uncertainties in the economic estimates used in the projections described above. The Company determines the fair values of these assets as of the acquisition date using discounted cash flow models. These models require the use of significant estimates and assumptions, including but not limited to:

§	estimating the timing of and expected costs to complete the in-process projects;

§	projecting the likelihood and timing of regulatory approvals;

§	estimating future cash flows from product sales resulting from completed products and in-process projects; and

§	developing appropriate discount rates and probability rates by project.

The Company believes the fair values assigned to the IPR&D assets acquired are based upon reasonable estimates and assumptions given available facts and circumstances as of the acquisition dates. The underlying assumptions and estimates used to value these IPR&D assets are subject to change in the future, and actual results may differ significantly from the assumptions and estimates. The Company's IPR&D assets are assessed for impairment on an annual basis or more frequently if indicators of impairment are present. The Company has selected October 1^st as its annual impairment test date.

Goodwill

The Company assesses the carrying value of goodwill on an annual basis, or whenever events or changes in circumstances indicate the carrying value of goodwill may not be recoverable, to determine whether any impairment in this asset may exist and, if so, the extent of such impairment. The provisions of the relevant accounting guidance require that the Company perform a two-step impairment test. In the first step, the Company compares the fair value of its reporting unit to the carrying value of the reporting unit. If the carrying value of the reporting unit exceeds the fair value of the reporting unit, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting unit's goodwill. If the carrying value of the reporting unit's goodwill exceeds its implied fair value, an impairment loss equal to the difference is recorded and charged to general and administrative expense. The Company calculates the fair value of the reporting unit utilizing the income approach. The income approach utilizes a discounted cash flow model, using a discount rate based on the Company's estimated weighted average cost of capital.

The determination of the fair value of a reporting unit is judgmental in nature and involves the use of significant estimates and assumptions. The estimates and assumptions used in calculating fair value include identifying future cash flows, which requires that the Company makes a number of critical legal, economic, market and business assumptions that reflect best estimates as of the testing date. The Company's assumptions and estimates may differ significantly from actual results, or circumstances could change that would cause the Company to conclude that an impairment now exists or that it previously understated the extent of impairment. The Company selected October 1^st as its annual impairment test date.

Impairment of long-lived assets

The Company assesses the recoverability of its long-lived assets for which an indicator of impairment exists by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. If the Company concludes that the carrying value will not be recovered, the Company measures the amount of such impairment by comparing the fair value to the carrying value.

Research and development

Research and development costs are expensed as incurred. Research and development costs primarily consist of salaries and fees paid to outside service providers and the costs of materials used in clinical trials and research and development. Other research and development expenses include fees paid to consultants, materials and related expenses for personnel and facility expenses.

Comprehensive income

Comprehensive income is comprised of net income and other changes in equity that are excluded from net income. The Company includes translation gains and losses incurred when converting its subsidiaries' financial statements from their functional currency to the U.S. dollar in accumulated other comprehensive income.

Foreign currencies

The local currency is the functional currency for the Company's foreign subsidiaries and, as such, assets and liabilities are translated into U.S. dollars at year-end exchange rates. Income and expense items are translated at average exchange rates during the year. Translation adjustments resulting from this process are charged or credited to other comprehensive income.

Capitalized interest

The Company capitalizes interest based on the cost of major ongoing capital projects which have not yet been placed in service. For the years ended December 31, 2012, 2011 and 2010, the Company incurred interest of $2.2 million, $1.7 million and $1.8 million, respectively. Of these amounts, the Company capitalized $2.2 million, $1.7 million and $1.8 million, respectively.

Certain risks and uncertainties

The Company has derived substantially all of its revenue from sales of BioThrax under contracts with the U.S. government. The Company's CDC contract does not necessarily increase the likelihood that it will secure future comparable contracts with the U.S. government. The Company expects that a significant portion of the business that it will seek in the near future, in particular for BioThrax, will be under government contracts that present a number of risks that are not typically present in the commercial contracting process. U.S. government contracts for BioThrax are subject to unilateral termination or modification by the government. The Company may fail to achieve significant sales of BioThrax to customers in addition to the U.S. government, which would harm its growth opportunities. The Company may not be able to sustain or increase profitability. The Company is spending significant amounts for the expansion of its manufacturing facilities. The Company may not be able to manufacture BioThrax consistently in accordance with FDA specifications. Other than BioThrax, all of the Company's product candidates are undergoing clinical trials or are in early stages of development, and failure is common and can occur at any stage of development. None of the Company's product candidates other than BioThrax have received regulatory approval.

Earnings Per Share

Basic net income per share of common stock excludes dilution for potential common stock issuances and is computed by dividing net income by the weighted average number of shares outstanding for the period. Diluted net income per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock.

Accounting for stock-based compensation

The Company has two stock-based employee compensation plans, the Second Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan (the "2006 Plan") and the Emergent BioSolutions Employee Stock Option Plan (the "2004 Plan" and together with the 2006 Plan, the "Emergent Plans"). The Company has granted options to purchase shares of common stock under the Emergent Plans and has granted restricted stock units under the 2006 Plan. The Emergent Plans have both incentive and non-qualified stock option features. The Company no longer grants equity awards under the 2004 Plan.

On May 17, 2012, the Company's shareholders approved amendments to the 2006 Plan, which increased the number of shares of common stock available for issuance under plan awards by 2,500,000. As of December 31, 2012, an aggregate of 11,178,826 shares of common stock were authorized for issuance under the 2006 Plan, of which a total of 3,752,260 shares of common stock remain available for future awards to be made to plan participants. As part of the May 2012 amendment, awards of restricted stock units after May 17, 2012 are counted against the maximum aggregate number of shares of common stock available for issuance under the 2006 Plan as 1.86 shares of common stock for every one restricted stock unit granted. The maximum number of shares subject to awards that may be granted per year under the 2006 Plan to a single participant is 287,700. The exercise price of each option must be not less than 100% of the fair market value of the shares underlying such option on the date of grant. Awards granted under the 2006 Plan have a contractual life of no more than 10 years. The terms and conditions of equity awards (such as price, vesting schedule, term and number of shares) under the Emergent Plans are determined by the compensation committee of the Company's board of directors, which administers the Emergent Plans. Each equity award granted under the Emergent Plans vests as specified in the relevant agreement with the award recipient and no option can be exercised after ten years from the date of grant.

The Company determines the fair value of restricted stock units using the closing market price of the Company's common stock on the day prior to the date of grant. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all stock options granted. The fair value of each option is estimated on the date of grant. Set forth below are the assumptions used in valuing the stock options granted and a discussion of the Company's methodology for developing each of the assumptions used:

	Year Ended December 31,
	2012			2011			2010
Expected dividend yield		0	%		0	%		0	%
Expected volatility		41-52	%		60	%		55	%
Risk-free interest rate		0.36-0.54	%		0.35-1.04	%		0.49-1.46	%
Expected average life of options	3.4 years			3.4 years			3.4 years

§	Expected dividend yield — the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.

Expected volatility — a measure of the amount by which a financial variable, such as share price, has fluctuated (historical volatility) or is expected to fluctuate (implied volatility) during a period. The Company analyzed its own historical volatility to estimate expected volatility over the same period as the expected average life of the options.

§	Risk-free interest rate — the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.

§	Expected average life of options — the period of time that options granted are expected to remain outstanding, based primarily on the Company's expectation of optionee exercise behavior subsequent to vesting of options.

Recent accounting pronouncements

In June 2011, the FASB issued ASU No. 2011-05, which amended ASC Topic 220 regarding presentation of comprehensive income. The amendments in ASU No. 2011-05 require that all nonowner changes in stockholders' equity be presented either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In the two-statement approach, the first statement should present total net income and its components followed consecutively by a second statement that should present total other comprehensive income, the components of other comprehensive income, and the total of comprehensive income. This amendment is effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. The Company elected to present comprehensive income in two separate but consecutive statements as part of the consolidated financial statements included in this Annual Report on Form 10-K.

Fair value measurements

12 Months Ended

Dec. 31, 2012

Fair value measurements [Abstract]

Fair value measurements

3. Fair value measurements

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	At December 31, 2012
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	42,720	$	-	$	-	$	42,720
Total assets		$	42,720	$	-	$	-	$	42,720


	At December 31, 2011
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	73,005	$	-	$	-	$	73,005
U.S. Treasury securities (2)			-		1,966		-		1,966
Total assets		$	73,005	$	1,966	$	-	$	74,971

Liabilities:
Contingent value rights		$	-	$	-	$	4,753	$	4,753
Total liabilities		$	-	$	-	$	4,753	$	4,753

(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.

(2) Included in investments in accompanying consolidated balance sheets.

As of December 31, 2012 and 2011, the Company did not have any transfers between Level 1 and Level 2 assets or liabilities.

The fair value of the CVR obligations is based on management's assessment of certain development and collaboration milestones, which are inputs that have no observable market (Level 3). The obligation is measured using a discounted cash flow model. For the year ended December 31, 2012, the Company recorded a decrease in the CVR obligations of $3.0 million due to Pfizer ceasing development of programs related to the CVR milestones and made a $1.7 million CVR payment under the Company's agreement with Abbott. For the year ended December 31, 2011, the Company recorded an increase of $221,000 in the value for the CVRs, due to an adjustment to the discount rates along with an update to the probability and estimated timing of achievement for certain development milestones, and made a $10.0 million CVR payment under the Abbott agreement. The adjustments to fair value are classified in the Company's statement of operations as research and development expense within the Company's Biosciences segment.

The following table is a reconciliation of the beginning and ending balance of the liabilities measured at fair value using significant unobservable inputs (Level 3) during the year ended December 31, 2012 and 2011.

(in thousands)
Balance at January 1, 2011	$	14,532
Expense (income) included in earnings		221
Settlements		(10,000	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at December 31, 2011		4,753
Expense (income) included in earnings		(3,005	)
Settlements		(1,748	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at December 31, 2012	$	-

Separate disclosure is required for assets and liabilities measured at fair value on a recurring basis, as documented above, from those measured at fair value on a nonrecurring basis. During the year ended December 31, 2012, the Company's SBI-087 IPR&D asset was measured at fair value on a nonrecurring basis (see Note 8), which is categorized as a level 3 fair value measurement. As of December 31, 2012 and 2011, the Company had no other assets or liabilities that were measured at fair value on a nonrecurring basis.

Both the carrying value and fair value of long-term indebtedness at December 31, 2012 and 2011 were $62.8 million and $59.5 million, respectively.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7578670&loc=d3e19207-110258

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14172-108612

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13537-108611

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=6957238&loc=d3e14064-108612

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13504-108611

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=7491637&loc=d3e13433-108611

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15B
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44A, 44B
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 159
-Paragraph 17-22, 27, 28
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15A
-Subparagraph a-d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 15C, 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 157
-Paragraph 32, 33, 34
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 107
-Paragraph 3, 10, 14, 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Investments

12 Months Ended

Dec. 31, 2012

Investments [Abstract]

Investments

4. Investments

The Company has no available-for-sale securities at December 31, 2012. In 2011, the Company invested in U.S. Treasury Securities that were short in duration. The following is a summary of the Company's available-for-sale securities at December 31, 2011:

	At December 31, 2011
(in thousands)	Amortized Costs		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Market Value
U.S. Treasury securities	$	1,966	$	-	$	-	$	1,966

The estimated fair value and amortized cost of investments available-for-sale by contractual maturity are due in one year or less. Unrealized gains and losses on cash equivalents and available-for-sale securities are included in accumulated other comprehensive income in the accompanying consolidated balance sheets. As of December 31, 2012 and 2011, the unrealized losses on investments were immaterial.

- Definition

The entire disclosure for investments in certain debt and equity securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-Glossary Debt Security
-URI http://asc.fasb.org/extlink&oid=6509901

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6379141&loc=d3e15032-111544

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-Glossary Equity Security
-URI http://asc.fasb.org/extlink&oid=6511694

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27232-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27405-111563

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 3, 19, 20, 21, 22, 137
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Accounts receivable

12 Months Ended

Dec. 31, 2012

Accounts receivable [Abstract]

Accounts receivable

5. Accounts receivable

Accounts receivable consist of the following:

	December 31,
(in thousands)	2012		2011
Billed	$	76,155	$	55,188
Unbilled		19,888		18,965
Total	$	96,043	$	74,153

- Definition

The entire disclosure for claims held for amounts due a entity, excluding financing receivables. Examples include, but are not limited to, trade accounts receivables, notes receivables, loans receivables. Includes disclosure for allowance for credit losses.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5066-111524

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.3,4)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5162-111524

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=7512638&loc=d3e5074-111524

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Statement of Position (SOP)
-Number 01-6
-Paragraph 13
-Subparagraph d
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 3, 4
-Article 5

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 7
-Article 9

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

+ Details

Inventories

12 Months Ended

Dec. 31, 2012

Inventories [Abstract]

Inventories

6. Inventories

Inventories consist of the following:

	December 31,
(in thousands)	2012		2011
Raw materials and supplies	$	2,733	$	2,313
Work-in-process		9,813		10,149
Finished goods		2,615		2,199
Total inventories	$	15,161	$	14,661

Property, plant and equipment

12 Months Ended

Dec. 31, 2012

Property, plant and equipment [Abstract]

Property, plant and equipment

7. Property, plant and equipment

Property, plant and equipment consist of the following:

	December 31,
(in thousands)	2012			2011
Land and improvements	$	4,839		$	4,115
Buildings, building improvements and leasehold improvements		66,953			26,122
Furniture and equipment		91,772			42,135
Software		15,691			11,854
Construction-in-progress		105,452			157,206
		284,707			241,432
Less: Accumulated depreciation and amortization		(42,943	)		(32,459	)
Total Property, plant and equipment, net	$	241,764		$	208,973

For the year ended December 31, 2012, construction-in-progress included costs related to Building 55, the Company's large-scale manufacturing facility, for which the Company is in the process of receiving regulatory approval. For the year ended December 31, 2011, construction-in-progress included costs related to Building 55, along with costs related to the purchase and renovation of the Company's manufacturing facility in Baltimore, Maryland.

Depreciation and amortization expense was $11.2 million, $9.4 million and $6.0 million for the years ended December 31, 2012, 2011 and 2010, respectively. As of December 31, 2012, 2011 and 2010 there was no unamortized internal use software-cost.

- Definition

The entire disclosure for long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software. This disclosure may include property plant and equipment accounting policies and methodology, a schedule of property, plant and equipment gross, additions, deletions, transfers and other changes, depreciation, depletion and amortization expense, net, accumulated depreciation, depletion and amortization expense and useful lives, income statement disclosures, assets held for sale and public utility disclosures.

+ References + Details

In-process research and development and goodwill

12 Months Ended

Dec. 31, 2012

In-process research and development and goodwill [Abstract]

In-process research and development and goodwill

8.	In-process research and development and goodwill

During the year ended December 31, 2012, Pfizer terminated its development programs with respect to the Company's SBI-087 product candidate. The Company considered this termination a potential indicator of impairment of the related SBI-087 IPR&D asset, and assessed the fair value of this asset. As part of the assessment, the Company considered the impact of Pfizer's decision, along with the Company's decision to no longer pursue further development of this asset due to reduced overall probability of success and increased development costs for the product candidate. As a result, the Company recorded an impairment charge of $9.6 million during the year ended December 31, 2012, which represented the entire carrying value of the SBI-087 IPR&D asset. This charge is classified in the Company's statement of operations as impairment of in-process research and development, within the Company's Biosciences segment.

As a result of the impairment of the SBI-087 IPR&D asset, the Company also performed an analysis of the Biosciences therapeutic reporting unit, which contains all goodwill reported on the Company's consolidated balance sheets as of December 31, 2012. Based on the analysis, the Company concluded that goodwill was not more likely than not impaired and therefore an interim impairment analysis was deemed unnecessary.

The Company completed its annual impairment assessment for its IPR&D assets and goodwill as of October 1, 2012 and 2011, respectively, and determined that the fair value of the IPR&D assets and goodwill was in excess of carrying value. On December 21, 2011, Abbott notified the Company that it was terminating the collaboration agreement effective March 20, 2012. The Company determined the Abbott termination of the collaboration agreement was an indication of a potential impairment of the Company's TRU-016 IPR&D asset and goodwill. The Company performed an assessment and determined that there was no interim impairment of these assets as of December 31, 2011. The Company has determined that all of its IPR&D assets and goodwill are included in the Biosciences therapeutics reporting unit, a component of the Biosciences business segment.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Assets held for sale	12 Months Ended
Assets held for sale	Dec. 31, 2012
Assets held for sale [Abstract]
Assets held for sale	9. Assets held for sale During the year ended December 31, 2012, the Company completed the sale of two buildings¸ which were classified as assets held for sale, for $12.2 million. The Company realized proceeds equal to the carrying value, less cost to sell, of these buildings and there was no gain or loss on the sale. The Company recorded the assets held for sale at fair market value, based on factors that include recent purchase offers less estimated selling costs. There was no impairment charge for the year ended December 31, 2012. The Company recorded impairment charges of $1.0 million and $1.2 million for the years ended December 31, 2011 and 2010, respectively, which are classified in the Company's statement of operations as selling, general and administrative expense within the Company's Biosciences segment.

Long-term debt

12 Months Ended

Dec. 31, 2012

Long-term debt [Abstract]

Long-term debt

10. Long-term debt

The components of long-term indebtedness are as follows:

	December 31,
(in thousands)	2012			2011
Construction loan dated July 2011; one month LIBOR plus 3%, due July 2017	$	29,375		$	26,095
Equipment loan dated August 2011; one month LIBOR plus 3%, due December 2017		11,068			1,426
Term loan dated December 2009; three month LIBOR plus 3.25%, due December 2014		18,200			19,717
Term loan dated November 2009; three month LIBOR plus 3.25%, due November 2014		4,131			4,478
Loan dated October 2004; 3.0%, repaid in March 2012		-			2,500
Term loan dated October 2004; 3.48%, repaid in March 2012		-			5,238
Total long-term indebtedness		62,774			59,454
Less current portion of long-term indebtedness		(4,470	)		(5,360	)
Noncurrent portion of long-term indebtedness	$	58,304		$	54,094

In August 2011, the Company entered into a loan agreement with PNC Bank ("PNC") to provide the Company with an equipment loan of up to $12.0 million to fund equipment purchases at the Company's Baltimore, Maryland product development and manufacturing facility. Under the equipment loan agreement, PNC agreed to make advances to the Company of up to $12.0 million through December 2012 based on periodic requests from the Company. The Company was required to make monthly interest only payments through December 2012. Beginning in December 2012, the Company is required to make monthly payments of principal of $92,000 plus interest with a balloon payment for the remaining unpaid principal and interest. The loan is collateralized by the equipment purchased. The annual interest rate is based on the one month LIBOR plus 3.0% and equaled 3.21% as of December 31, 2012.

In July 2011, the Company entered into a loan agreement and related agreements with PNC, under which PNC agreed to provide the Company with a construction loan of up to $30.0 million, primarily to fund the renovation and improvement of the Baltimore facility. A portion of the loan was also used to repay the Company's loan with HSBC Bank, which the Company used to finance a portion of the purchase price of the facility. Under the Company's loan agreement with PNC, PNC agreed to make advances to the Company of up to $30.0 million through July 2012. The Company was required to make monthly interest only payments through July 2012. Beginning in July 2012, the Company is required to make monthly payments of $125,000 plus interest with a balloon payment for the remaining unpaid principal and interest due in July 2017. Payment of the loan is secured by the Baltimore building along with Emergent BioDefense Operations Lansing LLC's accounts receivable under the Company's BioThrax supply contracts. The annual interest rate is based on the one month LIBOR plus 3.0% and equaled 3.21% as of December 31, 2012.

Under the terms of the construction and equipment loans with PNC, the Company is required to maintain certain financial covenants including minimum cash and liquid investments balance of $50.0 million, a leverage ratio of less than 2.0 and a debt coverage ratio of not less than 1.25 to 1.00. The leverage ratio is calculated by dividing the funded debt by net income before interests, taxes, depreciation, amortization, equity award compensation, non-cash development expenses from joint ventures, write-ff off intangibles and changes in fair value of contingent value rights for the most recent four quarters. The debt coverage ratio is calculated by dividing net income before interests, taxes, depreciation, amortization, equity award compensation, non-cash development expenses from joint ventures, write-ff off intangibles and changes in fair value of contingent value rights for the most recent four quarters less cash taxes by the sum of current obligation and interest expenses for borrowed money, in each case due and payable following four quarters. The Company was in compliance with these covenants as of December 31, 2012 and 2011.

In December 2009, the Company entered into a loan agreement with HSBC, under which HSBC provided the Company with a term loan of $22.8 million. This loan replaced a prior loan arrangement with HSBC under which HSBC agreed to loan the Company $30.0 million. Under the new loan agreement, the Company is required to make monthly payments in the amount of $126,000 in principal plus accrued interest, with a residual principal payment due upon maturity in December 2014. Payment of the loan is secured by substantially all of the assets of Emergent BioDefense Operations, other than accounts receivable under BioThrax supply contracts with the U.S. government. The annual interest rate is based on the three month LIBOR plus 3.25% and equaled 3.56% as of December 31, 2012 and 2011.

In November 2009, the Company acquired a development and manufacturing facility in Baltimore, Maryland for $8.2 million. The Company paid approximately $1.2 million in cash and financed the remaining balance with a term loan from HSBC in the amount of $7.0 million. This loan was repaid in July 2011.

In October 2009, the Company acquired a research and development facility in Gaithersburg, Maryland for $6.4 million. The Company paid $1.2 million in cash and financed the remaining balance with a term loan from HSBC in the amount of $5.2 million. This loan requires monthly principal payments of $29,000 plus accrued interest from November 2009 through November 2014 with a balloon payment for the remaining unpaid principal and interest due in November 2014. The loan is collateralized by the facility. The annual interest rate is based on the three month LIBOR plus 3.25% and equaled 3.56% as of December 31, 2012.

In April 2006, the Company acquired a 145,000 square foot facility in Frederick, Maryland for $9.8 million. This facility was previously under a lease which contained an option to purchase the facility. The Company paid $1.3 million in cash and financed the remaining balance with a bank loan with HSBC in the amount of $8.5 million. The loan was repaid in April 2011.

Under the terms of the loans the Company has with HSBC, the Company is required to maintain a book leverage ratio of less than 1.00. This ratio is calculated by dividing total liabilities, excluding deferred revenues specific to contracts with the U.S. government, by total net worth. In addition, the Company is required to maintain a debt coverage ratio of not less than 1.25 to 1.00. This ratio is calculated by dividing earnings before interest, taxes, depreciation and amortization for the most recent four quarters by the sum of current obligations under capital leases and principal obligations and interest expenses for borrowed money, in each case due and payable for the following four quarters. The Company was in compliance with these covenants as of December 31, 2012 and 2011.

In October 2004, the Company entered into a Secured Conditional Loan with the Maryland Economic Development Assistance Fund ("MEDAF") for $2.5 million. The proceeds of the loan were used to reimburse the Company for eligible costs it incurred to purchase a building in Frederick, Maryland. The loan was secured by a $1.3 million letter of credit and a security interest in the building. The loan was repaid in March 2012.

In connection with the 2004 purchase of the building in Frederick, Maryland, the Company entered into a loan agreement for $7.0 million with PNC to finance the remaining portion of the purchase price. The loan was repaid in March 2012.

Scheduled principal repayments and maturities on long-term debt as of December 31, 2012 are as follows:

(in thousands)
2013	$	4,470
2014		23,075
2015		2,607
2016		2,607
2017		30,015
	$	62,774

Stockholders' equity

12 Months Ended

Dec. 31, 2012

Stockholders' equity [Abstract]

Stockholders' equity

11. Stockholders' equity

Preferred stock

The Company is authorized to issue up to 15,000,000 shares of preferred stock, $0.001 par value per share ("Preferred Stock"). Any Preferred Stock issued may have dividend rights, voting rights, conversion privileges, redemption characteristics, and sinking fund requirements as approved by the Company's board of directors.

Common stock

The Company currently has one class of common stock, $0.001 par value per share common stock ("Common Stock"), authorized and outstanding. The Company is authorized to issue up to 100,000,000 shares of Common Stock. Holders of Common Stock are entitled to one vote for each share of Common Stock held on all matters, except as may be provided by law.

Treasury stock

On May 17, 2012, the Company's Board of Directors authorized the repurchase of up to $35.0 million of its common stock through a share repurchase program. The repurchase program terminates on December 31, 2013. Under the program, the Company is authorized to repurchase shares through Rule 10b5−1 plans, open market purchases, block purchases or otherwise in accordance with applicable federal securities laws, including Rule 10b−18 of the Securities Exchange Act of 1934. This share repurchase program does not obligate the Company to acquire any specific number of shares and may be suspended or discontinued at any time. The timing and amount of the shares to be repurchased will be based on market conditions and other factors, including price, corporate and regulatory requirements, and alternative investment opportunities. The Company repurchased 398,481 shares for $5.8 million during the year ended December 31, 2012. In addition, in December 2012, in a form of stock transaction provided for under the terms of our stock incentive plan and stock option agreement, the Company engaged in a transaction with its chief executive officer in which the Company acquired 4,677 shares of common stock, valued at $74,000 as payment of the exercise price for 7,300 options.

Employee Stock Purchase Plan

On May 17, 2012, the Company's shareholders approved the 2012 Employee Stock Purchase Plan ("ESPP"), as defined in Section 423 of the Internal Revenue Code of 1986. All employees of the Company are eligible to participate in the ESPP, except those owning 5% or more of the Company's stock. One million shares of common stock have been approved for the ESPP. The ESPP has two plan periods: December 1^st to May 31^st and June 1^st to November 30^th. Employees are permitted to contribute between 1% and 10% of compensation during a plan period. The ESPP allows for employees to purchase shares of the Company's stock at a 15% discount at the end of each plan period based on the share price at that time. The maximum number of shares an employee may purchase during any plan period is 800 shares. The Company utilizes the Black-Scholes valuation model for estimating the fair value of all shares under its ESPP. The fair value of each option is estimated on the date of grant. During the year ended December 31, 2012, the Company recorded stock-based compensation expense of $11,000 related to the ESPP.

Stock options and restricted stock units

The following is a summary of option award activity under the Emergent Plans:

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2011		3,090,909		$	17.35		53,156	$	8.86	$	6,238,427
Exercisable at December 31, 2011		1,459,049		$	14.19		53,156	$	8.86	$	5,650,832
Granted		785,941			15.65		-		-
Exercised		(89,125	)		8.53		-		-
Forfeited		(221,328	)		19.24		-		-
Outstanding at December 31, 2012		3,566,397		$	17.08		53,156	$	8.86	$	4,802,547
Exercisable at December 31, 2012		2,151,700		$	16.26		53,156	$	8.86	$	4,477,056
Options expected to vest at December 31, 2012		1,056,036		$	18.15		-	$	-	$	245,395

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2011		635,500		$	20.89	$	10,714,450
Granted		413,022			15.61
Vested		(260,738	)		15.22
Forfeited		(67,716	)		19.36
Outstanding at December 31, 2012		720,068		$	20.89	$	11,549,891

The weighted average remaining contractual term of options outstanding as of December 31, 2012 and 2011 was 4.2 and 4.9 years, respectively. The weighted average remaining contractual term of options exercisable as of December 31, 2012 and 2011 was 3.5 and 4.1 years, respectively.

The weighted average grant date fair value of options granted during the years ended December 31, 2012, 2010 and 2009 was $5.16, $10.09 and $6.48 respectively. The total intrinsic value of options exercised during the years ended December 31, 2012, 2011 and 2010 was $589,000, $10.2 million and $7.5 million, respectively. The total fair value of awards vested during 2012, 2011 and 2010 was $10.3 million, $7.9 million and $5.8 million, respectively.

Stock-based compensation expense was recorded in the following financial statement line items:

	December 31,
(in thousands)	2012		2011		2010
Cost of product sales	$	513	$	466	$	324
Research and development		3,451		3,203		1,635
Selling, general and administrative		7,151		7,070		5,104
Total stock-based compensation expense	$	11,115	$	10,739	$	7,063

- Definition

The entire disclosure for shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interest, if any, including other comprehensive income (as applicable). Including, but not limited to: (1) balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings; (2) accumulated balance for each classification of other comprehensive income and total amount of comprehensive income; (3) amount and nature of changes in separate accounts, including the number of shares authorized and outstanding, number of shares issued upon exercise and conversion, and for other comprehensive income, the adjustments for reclassifications to net income; (4) rights and privileges of each class of stock authorized; (5) basis of treasury stock, if other than cost, and amounts paid and accounting treatment for treasury stock purchased significantly in excess of market; (6) dividends paid or payable per share and in the aggregate for each class of stock for each period presented; (7) dividend restrictions and accumulated preferred dividends in arrears (in aggregate and per share amount); (8) retained earnings appropriations or restrictions, such as dividend restrictions; (9) impact of change in accounting principle, initial adoption of new accounting principle and correction of an error in previously issued financial statements; (10) shares held in trust for Employee Stock Ownership Plan (ESOP); (11) deferred compensation related to issuance of capital stock; (12) note received for issuance of stock; (13) unamortized discount on shares; (14) description, terms, and number of warrants or rights outstanding; (15) shares under subscription and subscription receivables, effective date of new retained earnings after quasi-reorganization and deficit eliminated by quasi-reorganization and, for a period of at least ten years after the effective date, the point in time from which the new retained dates; and (16) retroactive effective of subsequent change in capital structure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=6228006&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=6959260&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section B
-Paragraph 7, 11A
-Chapter 1
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 12
-Paragraph 10
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 16: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 5
-Paragraph 15
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 17: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph d
-Article 4

Reference 18: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 02
-Paragraph 29, 30, 31
-Article 5

Reference 19: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 20: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Article 4

Reference 21: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

Reference 22: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 129
-Paragraph 2, 3, 4, 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 23: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Article 3

+ Details

Variable interest entities	12 Months Ended
Variable interest entities	Dec. 31, 2012
Variable interest entities [Abstract]
Variable interest entities	13. Variable interest entities In July 2008, the Company entered into a collaboration with the University of Oxford ("Oxford") and certain Oxford researchers to advance a vaccine product candidate for tuberculosis, resulting in the formation of the Oxford-Emergent Tuberculosis Consortium ("OETC"). The Company has a 51% equity interest in OETC and controls the OETC Board of Directors. In addition, the Company had certain funding and service obligations related to its investment. As a result of clinical trial data for the Company's tuberculosis vaccine product candidate published in February 2012, the Company expects future funding of OETC to be minimal. The Company evaluates its variable interests in OETC on a quarterly basis and has determined that it is the primary beneficiary as it has the power to direct the activities of OETC that most significantly impact OETC's economic performance and will absorb the majority of expected losses. Accordingly, the Company consolidates OETC. As of December 31, 2012 and 2011, respectively, assets of $2.0 million and $461,000 and liabilities of $2.0 million and $947,000 related to OETC were included within the Company's consolidated balance sheets. During the year ended December 31, 2012, OETC incurred net losses of $10.7 million of which $5.4 million is included in the Company's consolidated statement of operations. During the year ended December 31, 2011, OETC incurred net losses of $13.2 million, of which $6.7 million is included in the Company's consolidated statement of operations. In conjunction with the establishment of OETC, the Company granted a put option to Oxford and certain Oxford researchers whereby the Company may be required to acquire all of the OETC shares held by Oxford and the Oxford researchers at the fair market value of the underlying shares. This put option is contingent upon the satisfaction of a number of conditions that must exist or occur subsequent to the granting by the European Commission of marketing authorization for the OETC-sponsored tuberculosis vaccine product candidate. The Company accounts for the put option in accordance with the accounting provisions related to derivatives and distinguishing liabilities from equity. In accordance with these provisions, the Company has determined that the put option had no value as of December 31, 2012.

- Definition

The entire disclosure for noncontrolling interest in consolidated subsidiaries, which could include the name of the subsidiary, the ownership percentage held by the parent, the ownership percentage held by the noncontrolling owners, the amount of the noncontrolling interest, the location of this amount on the balance sheet (when not reported separately), an explanation of the increase or decrease in the amount of the noncontrolling interest, the noncontrolling interest share of the net Income or Loss of the subsidiary, the location of this amount on the income statement (when not reported separately), the nature of the noncontrolling interest such as background information and terms, the amount of the noncontrolling interest represented by preferred stock, a description of the preferred stock, and the dividend requirements of the preferred stock.

+ References + Details

Collaboration Agreements	12 Months Ended
Collaboration Agreements	Dec. 31, 2012
Collaboration Agreements [Abstract]
Collaboration Agreements	14. Collaboration Agreements Abbott Laboratories In August 2009, Trubion, which the Company acquired in October 2010, entered into a collaboration agreement with Facet Biotech Corporation, now a wholly-owned subsidiary of Abbott, for the joint worldwide development and commercialization of TRU-016. The collaboration agreement covered TRU-016 in all indications and all other CD37-directed protein therapeutics. The collaboration agreement was terminated on March 20, 2012 and all rights to TRU-016 and other CD37-directed protein therapeutics under the collaboration agreement reverted back to the Company. During the year ended December 31, 2012, 2011 and 2010, the Company recorded revenue of $2.7 million, $17.7 million and $1.2 million, respectively, for research and development services pursuant to the Abbott agreement, which are included in the Company's financial statements of operations as contracts and grants revenue within the Company's Biosciences segment. For the year ended December 31, 2012, the Company recorded $1.4 million related to deferred revenue recognition and $1.4 million for collaborative research funding. For the year ended December 31, 2011, the revenue is comprised of $10.5 million related to the recognition of deferred revenue, $6.0 million related to the achievement of a development milestone and $1.2 million for collaborative research funding. For the year ended December 31, 2010, the revenue is comprised of $831,000 related to the recognition of deferred revenue and $398,000 for collaborative research funding. As of December 31, 2012, there were no receivables or payables under the agreement. As of December 31, 2011, the Company had a net receivable of $6.8 million. Pfizer Inc. In December 2005, Trubion entered into an agreement (the "Pfizer Agreement") with Wyeth Pharmaceuticals, now a wholly-owned subsidiary of Pfizer, for the development and worldwide commercialization of CD20-directed therapeutics. In September 2012, the Pfizer Agreement was terminated. The Company's right to receive royalty payments under the Biosimilar Amendment survives termination of the Pfizer Agreement. During the year ended December 31, 2012, 2011 and 2010, the Company recorded revenue of $1.2 million, $1.9 million and $992,000, respectively, for research and development services pursuant to the Pfizer agreement, which are included in the Company's financial statements of operations as contracts and grants revenue within the Company's Biosciences segment. For the year ended December 31, 2012, the Company recorded $68,000 related to deferred revenue recognition and $1.1 million for collaborative research funding. For the year ended December 31, 2011, the revenue is comprised of $52,000 related to the recognition of deferred revenue and $1.8 million for collaborative research funding. For the year ended December 31, 2010, the revenue is comprised of $9,000 related to the recognition of deferred revenue and $983,000 for collaborative research funding. As of December 31, 2012 and 2011, the Company has a receivable of $52,000 and $302,000, respectively.

Restructuring

12 Months Ended

Dec. 31, 2012

Restructuring [Abstract]

Restructuring

15.	Restructuring

In November 2010, the Company adopted a plan to restructure and reprioritize the operations of Emergent Product Development UK Limited ("EPDU"). The restructuring was completed by the year ended December 31, 2011. For the years ended December 31, 2011 and 2010, the Company incurred restructuring expenses of $3.1 million and $2.5 million, respectively, which is included in selling, general and administrative expense in the Company's statement of operations, and is included within the Biosciences segment.

The Company has completed this restructuring. The costs of the restructuring are detailed below:

	Incurred in		Inception to Date		Total
(in thousands)	2011		Costs Incurred		Incurred
Termination benefits	$	475	$	2,893	$	2,893
Contract termination costs		1,923		2,295		2,295
Other costs		90		350		350
Total	$	2,488	$	5,538	$	5,538

The following is a summary of the activity for the liabilities related to the EPDU restructuring:

				Lease
	Termination			Termination
(in thousands)	Benefits			Costs			Total
Balance at December 31, 2010	$	2,418		$	650		$	3,068
Expenses incurred		475			1,923			2,398
Amount paid		(2,893	)		(2,295	)		(5,188	)
Other adjustments		-			(278	)		(278	)
Balance at December 31, 2011	$	-		$	-		$	-

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References + Details

Leases

12 Months Ended

Dec. 31, 2012

Leases [Abstract]

Leases

17. Leases

The Company leases laboratory and office facilities, office equipment and vehicles under various operating lease agreements. The Company leases office space and laboratory space in Munich, Germany under a non-cancelable operating lease that expires in June 2015. The Company leases primarily office space in Wokingham, England under an operating lease that expires in November 2016. The Company leases office space in Rockville, Maryland under an operating lease that contain a 3% annual escalation clause, which expires in December 2016, and the Company has a five-year renewal option at the end of the initial term. The Company leases office and laboratory space under an operating lease agreement in Seattle, Washington, which expires in April 2015. For the years ended December 31, 2012, 2011 and 2010, total lease expense was $3.6 million, $3.8 million and $2.6 million, respectively.

Future minimum lease payments under operating lease obligations as of December 31, 2012 were as follows:

(in thousands)
2013	$	3,447
2014		3,497
2015		2,331
2016		1,377
2017		-
Total minimum lease payments	$	10,652

- Definition

The entire disclosure for lessee entity's leasing arrangements including, but not limited to, all of the following: (a.) The basis on which contingent rental payments are determined, (b.) The existence and terms of renewal or purchase options and escalation clauses, (c.) Restrictions imposed by lease agreements, such as those concerning dividends, additional debt, and further leasing.

+ References + Details

Business Interruption Insurance Recovery	12 Months Ended
Business Interruption Insurance Recovery	Dec. 31, 2012
Business Interruption Insurance Recovery [Abstract]
Business Interruption Insurance Recovery [Text Block]	18. Business interruption insurance recovery During the year ended December 31, 2012, the Company recorded $1.7 million in insurance recovery related to a power outage at its Lansing, Michigan facility. The insurance recovery is classified in the Company's statement of operations as other income (expense), net.

Related party transactions	12 Months Ended
Related party transactions	Dec. 31, 2012
Related party transactions [Abstract]
Related party transactions	19. Related party transactions The Company entered into an agreement in February 2009 with an entity controlled by family members of the Company's Executive Chairman to market and sell BioThrax. The agreement was effective as of November 2008 and requires payment based on a percentage of net sales of biodefense products of 17.5% in Saudi Arabia and 15% in Qatar and United Arab Emirates, and reimbursement of certain expenses. No expenses were incurred under this agreement during 2012 and 2011. The Company entered into a consulting agreement in September 2010 with an entity controlled by the Company's former Senior Vice President Corporate Affairs, who is also a family member of the Company's Executive Chairman. The agreement, which terminated in August 2011, provided for consulting services in connection with special projects as assigned by the Company's President. During 2011 and 2010, the Company incurred approximately $35,000 and $25,000, respectively, for services rendered under this agreement, of which no balance remained in unpaid accounts payable at December 31, 2011. The Company was previously a party to a consulting agreement with a member of the Company's Board of Directors. In October 2011, this director resigned from the Company's Board of Directors, and the consulting agreement was terminated in November 2011. During the years ended 2011 and 2010, the Company incurred approximately $225,000 and $180,000 under this agreement for strategic consultation and project support for the Company's marketing and communications group, of which no balance remained unpaid in accounts payable at December 31, 2011.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39622-107864

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39678-107864

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(k))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 850
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph b
-Article 3A

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph k
-Article 4

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 57
-Paragraph 1-4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Earnings per share

12 Months Ended

Dec. 31, 2012

Earnings per share [Abstract]

Earnings per share

20. Earnings per share

The following table presents the calculation of basic and diluted net income (loss) per share:

	Year Ended December 31,
(in thousands, except share and per share data)	2012		2011		2010
Numerator:
Net income	$	23,524	$	23,019	$	51,698

Denominator:
Weighted-average number of shares—basic		36,080,495		35,658,907		31,782,286
Dilutive securities—equity awards		340,167		547,145		757,214
Weighted-average number of shares—diluted		36,420,662		36,206,052		32,539,500

Earnings per share-basic	$	0.65	$	0.65	$	1.63
Earnings per share-diluted	$	0.65	$	0.64	$	1.59

For the years ending December 31, 2012, 2011 and 2010, outstanding stock options to purchase approximately 2.9 million, 746,000 and 1.4 million shares of common stock, respectively, are not considered in the diluted earnings per share calculation because the exercise price of these options is greater than the average per share closing price during the year.

Segment information

12 Months Ended

Dec. 31, 2012

Segment information [Abstract]

Segment information

21.	Segment information

For financial reporting purposes, the Company reports financial information for two business segments: Biodefense and Biosciences. The Company's two business segments, or divisions, engage in business activities for which discrete financial information is reviewed by the chief operating decision maker. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies. The Company's reportable segments are business units that offer different products and product candidates and are managed separately because they manufacture and develop distinct products with different development processes.

The Biodefense division is directed to government-sponsored development and supply of countermeasures against potential agents of bioterror or biowarfare and targets the infectious disease anthrax. Revenues in this segment are primarily from sales of the Company's FDA-licensed product, BioThrax® (Anthrax Vaccine Adsorbed), to the U.S. government. The Biosciences division is directed to commercial opportunities and primarily targets oncology indications, and consists of two business units, therapeutics and vaccines. The "All Other" segment relates to the general operating costs of the Company and includes costs of the centralized services departments, which are not allocated to the other segments, as well as spending on activities that are not classified as Biodefense or Biosciences. The assets in this segment consist primarily of cash.

The Company's segment presentation for the years ended December 31, 2011 and 2010 have been reclassified to conform to the 2012 presentation. In the third quarter of 2012, as a result of the Company receiving a contract from the U.S. government to establish a Center for Innovation in Advanced Development and Manufacturing, the Company reevaluated its segments. The Company reclassified certain components of its segments to reflect the current presentation to, and review of, financial information by the chief operating decision maker. Total assets by reportable segments are not disclosed as these assets are not reviewed separately by the Company's chief operating decision maker.

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Year Ended December 31, 2012
External revenue	$	276,469	$	5,419		$	-		$	281,888
Intersegment revenue (expense)		-		-			-			-
Research and development		68,579		44,588			7,059			120,226
Interest revenue		-		-			134			134
Interest expense		-		-			(6	)		(6	)
Depreciation and amortization		8,951		2,147			99			11,197
Net income (loss)		94,865		(63,928	)		(7,413	)		23,524
In-process research and development assets		-		41,800			-			41,800
Goodwill		-		5,502			-			5,502
Total assets		354,010		56,148			154,072			564,230
Expenditures for long-lived assets		52,957		810			78			53,845
Year Ended December 31, 2011
External revenue	$	251,037	$	22,347		$	-		$	273,384
Intersegment revenue (expense)		-		-			-			-
Research and development		57,833		61,566			5,433			124,832
Interest revenue		-		-			105			105
Interest expense		-		-			-			-
Depreciation and amortization		6,213		3,070			72			9,355
Net income (loss)		86,836		(56,438	)		(7,379	)		23,019
In-process research and development assets		-		51,400			-			51,400
Goodwill		-		5,502			-			5,502
Total assets		290,302		92,321			164,241			546,864
Expenditures for long-lived assets		52,326		1,608			92			54,026
Year Ended December 31, 2010
External revenue	$	282,727	$	3,444		$	-		$	286,171
Intersegment revenue (expense)		-		-			-			-
Research and development		52,191		32,895			4,209			89,295
Interest revenue		-		-			832			832
Interest expense		-		-			-			-
Depreciation and amortization		4,584		1,333			73			5,990
Net income (loss)		113,249		(53,676	)		(7,875	)		51,698
In-process research and development assets		-		51,400			-			51,400
Goodwill		-		5,502			-			5,502
Total assets		216,529		99,754			184,036			500,319
Expenditures for long-lived assets		21,728		373			-			22,101

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 131
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Quarterly financial data (unaudited)

12 Months Ended

Dec. 31, 2012

Quarterly financial data (unaudited) [Abstract]

Quarterly financial data (unaudited)

22. Quarterly financial data (unaudited)

Quarterly financial information for the years ended December 31, 2012 and 2011 is presented in the following tables:

	Three months ended
(in thousands)	March 31,			June 30,		September 30,		December 31,
Fiscal year 2012
Revenue	$	50,311		$	70,379	$	66,592	$	94,606
Income (loss) from operations		(12,538	)		8,653		9,817		24,035
Net income (loss)		(6,829	)		7,632		6,617		16,104
Net income (loss) per share, basic		(0.19	)		0.21		0.18		0.45
Net income (loss) per share, diluted		(0.19	)		0.21		0.18		0.44
Fiscal year 2011
Revenue	$	18,533		$	88,141	$	58,762	$	107,948
Income (loss) from operations		(35,506	)		20,207		1,408		45,990
Net income (loss)		(21,397	)		14,210		1,549		28,657
Net income (loss) per share, basic		(0.61	)		0.40		0.04		0.80
Net income (loss) per share, diluted		(0.61	)		0.39		0.04		0.78

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References + Details

Income taxes

12 Months Ended

Dec. 31, 2012

Income taxes [Abstract]

Income taxes

12. Income taxes

Significant components of the provision for income taxes attributable to operations consist of the following:

	Year ended December 31,
(in thousands)	2012			2011			2010
Current
Federal	$	11,481		$	(3,795	)	$	16,664
State		(1,045	)		(1,110	)		187
International		103			74			102
Total current		10,539			(4,831	)		16,953
Deferred
Federal		3,758			19,055			10,003
State		(375	)		1,606			(774	)
Total deferred		3,383			20,661			9,229
Total provision for income taxes	$	13,922		$	15,830		$	26,182

The Company's net deferred tax asset consists of the following:

	December 31,
(in thousands)	2012			2011
Net operating loss carryforward	$	26,102		$	28,621
Research and development carryforward		3,556			3,556
Stock compensation		5,289			3,666
Foreign deferrals		64,009			61,255
Deferred revenue		-			485
Other		9,005			9,596
Deferred tax asset		107,961			107,179
Fixed assets		(22,040	)		(21,760	)
Other		(6,158	)		(6,902	)
Deferred tax liability		(28,198	)		(28,662	)
Valuation allowance		(67,412	)		(62,783	)
Net deferred tax asset	$	12,351		$	15,734

The Company currently has approximately $43.9 million in net operating loss carryforwards along with $3.6 million in research and development tax credit carryforwards for U.S. federal tax purposes that will begin to expire in 2026 and 2023, respectively. The U.S. federal tax carryforwards are recorded with no valuation allowance. The Company has $200.5 million in state net operating loss carryforwards, primarily in Maryland, that will begin to expire in 2018. The Company has approximately $223.3 million in net operating losses from foreign jurisdictions that will have an indefinite life unless the foreign entities have a change in the nature or conduct of the business in the three years following a change in ownership. These foreign net operating losses are recorded with a valuation allowance. The use of any of these net operating loss and research and development tax credit carryforwards may be restricted due to changes in the Company's ownership.

The provision for income taxes differs from the amount of taxes determined by applying the U.S. federal statutory rate to loss before provision for income taxes as a result of the following:

	Year ended December 31,
(in thousands)	2012			2011			2010
US	$	52,391		$	66,756		$	111,775
International		(14,945	)		(27,907	)		(33,895	)
Earnings before taxes on income		37,446			38,849			77,880

Federal tax at statutory rates	$	13,106		$	13,597		$	27,258
State taxes, net of federal benefit		(2,079	)		46			666
Impact of foreign operations		(3,604	)		(2,371	)		(7,713	)
Change in valuation allowance		4,629			3,193			6,394
Effect of foreign rates		(22	)		(12	)		(30	)
Tax credits		(2,904	)		(1,405	)		(1,754	)
Other differences		139			556			398
Permanent differences		4,657			2,226			963
Provision for income taxes	$	13,922		$	15,830		$	26,182

During the year ended December 31, 2012, the Company corrected certain immaterial prior period errors for the years ending December 31, 2011 and 2010 of approximately $2.4 million and $909,000, respectively. These immaterial errors related to the cash flow presentation of the excess tax benefit attributed to the exercise of non-qualified stock options and restricted stock units. The immaterial errors had no impact on the Company's consolidated cash flows, consolidated statements of income and comprehensive income or the consolidated balance sheets. The correction of the errors is reflected as a reduction of operating cash flow from operating activities and an increase in cash flow from financing activities.

The Company recognizes interest in interest expense and recognizes potential penalties related to unrecognized tax benefits in selling, general and administrative expense. The Company accrued approximately $25,000 and $26,000, for the payment of interest and penalties as of December 31, 2012 and 2011, respectively. Of the total unrecognized tax benefits recorded at December 31, 2012 and 2011, $153,000 and $104,000, respectively is classified as a current liability and $863,000 and $952,000, respectively, is classified as a non-current liability on the balance sheet. As of December 31, 2012 and 2011, the Company estimated that approximately, $75,000 and $50,000, respectively, of unrecognized tax benefits will reverse within the next twelve months.

The table below presents the gross unrecognized tax benefits activity for 2012, 2011 and 2010:

(in thousands)
Gross unrecognized tax benefits at January 1, 2010	$	260
Increases for tax positions for prior years		16
Decreases for tax positions for prior years		(175	)
Increases for tax positions for current year		849
Settlements		-
Lapse of statute of limitations		-
Gross unrecognized tax benefits at December 31, 2010		950
Increases for tax positions for prior years		167
Decreases for tax positions for prior years		(61	)
Increases for tax positions for current year		-
Settlements		-
Lapse of statute of limitations		-
Gross unrecognized tax benefits at December 31, 2011		1,056
Increases for tax positions for prior years		25
Decreases for tax positions for prior years		(65	)
Increases for tax positions for current year		-
Settlements		-
Lapse of statute of limitations		-
Gross unrecognized tax benefits at December 31, 2012	$	1,016

When resolved, substantially all of these reserves would impact the effective tax rate.

The Company's federal and state income tax returns for the tax years 2009 to 2011 remain open to examination. The Company's tax returns in the United Kingdom remain open to examination for the tax years 2011 to 2004, and tax returns in Germany remain open indefinitely.

As of December 31, 2012, the Company's 2008, 2009 and 2010 federal income tax returns are under audit by the Internal Revenue service. The Company believes appropriate provisions have been made for any outstanding issues.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

+ Details

401(k) savings plan	12 Months Ended
401(k) savings plan	Dec. 31, 2012
401(k) savings plan [Abstract]
401(k) savings plan	16. 401(k) savings plan The Company has established a defined contribution savings plan under Section 401(k) of the Internal Revenue Code. The 401(k) Plan covers substantially all employees. Under the 401(k) Plan, employees may make elective salary deferrals. The Company currently provides for matching of qualified deferrals up to 50% of the first 6% of the employee's salary. During the years ended December 31, 2012, 2011 and 2010, the Company made matching contributions of approximately $1.9 million, $1.8 million and $1.3 million, respectively.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 715
-URI http://asc.fasb.org/topic&trid=2235017

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Implementation Guide (Q and A)
-Number FAS88
-Paragraph 63
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 106
-Paragraph 518
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph a
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-2
-Paragraph 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 87
-Paragraph 264
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph q
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5
-Subparagraph h
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 8
-Subparagraph m
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 132R
-Paragraph 5, 6, 7, 8
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 158
-Paragraph 7, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS106-2
-Paragraph 20, 21, 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Principles Board Opinion (APB)
-Number 30
-Paragraph 26
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2012
Subsequent Events [Abstract]
Subsequent Events [Text Block]	23. Subsequent events In January 2013, the Company entered into an agreement to purchase an office building for $27.5 million. The Company plans to utilize a portion of the new building for its headquarters operations and continue to lease the remaining space under existing lease agreements with third parties. The Company anticipates the purchase will be completed during the first quarter of 2013. In February 2013, the Company initiated plans to close its operations in the United Kingdom and South Africa. The restructuring entails a headcount reduction of employees in the United Kingdom and South Africa, the termination of the UK facility lease, and the impairment of fixed assets. The Company expects to complete this restructuring during 2013, and estimates that the total cost of the restructuring will be approximately $3 million.

Summary of significant accounting policies (Policies)

12 Months Ended

Dec. 31, 2012

Summary of significant accounting policies [Abstract]

Basis of presentation and consolidation

Use of estimates

Cash and cash equivalents

Investment

Investments

Fair value of measurements

Level 1 — Observable inputs for identical assets or liabilities such as quoted prices in active markets;

Level 2 — Inputs other than quoted prices in active markets that are either directly or indirectly observable; and

The fair value of U.S. Treasury securities (Level 2) is obtained from an independent pricing service and is based on recent sales of similar securities and other observable market data.

Restricted cash

Significant customers and accounts receivable

Concentrations of credit risk

Inventories

Property, plant and equipment

Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:

Buildings	31-39 years
Building improvements	10-39 years
Furniture and equipment	3-15 years
Software	Lesser of 3-5 years or product life
Leasehold improvements	Lesser of the asset life or lease term

Income taxes

Revenue recognition

The Company recognizes revenues from product sales if four basic criteria have been met:

§	there is persuasive evidence of an arrangement;

§	delivery has occurred or title has passed to the Company's customer;

§	the fee is fixed or determinable; and

§	collectability is reasonably assured.

Contingent value rights

Acquired in process research and development

§	estimating the timing of and expected costs to complete the in-process projects;

§	projecting the likelihood and timing of regulatory approvals;

§	estimating future cash flows from product sales resulting from completed products and in-process projects; and

§	developing appropriate discount rates and probability rates by project.

Goodwill

Impairment of long-lived assets

Research and development

Comprehensive income

Foreign currencies

Capitalized interest

Certain risks and uncertainties

Earnings Per Share

Accounting for stock-based compensation

	Year Ended December 31,
	2012			2011			2010
Expected dividend yield		0	%		0	%		0	%
Expected volatility		41-52	%		60	%		55	%
Risk-free interest rate		0.36-0.54	%		0.35-1.04	%		0.49-1.46	%
Expected average life of options	3.4 years			3.4 years			3.4 years

§	Expected dividend yield — the Company does not pay regular dividends on its common stock and does not anticipate paying any dividends in the foreseeable future.

§	Risk-free interest rate — the range of U.S. Treasury rates with a term that most closely resembles the expected life of the option as of the date on which the option is granted.

§	Expected average life of options — the period of time that options granted are expected to remain outstanding, based primarily on the Company's expectation of optionee exercise behavior subsequent to vesting of options.

Recent accounting pronouncements

Summary of significant accounting policies (Tables)

12 Months Ended

Dec. 31, 2012

Summary of significant accounting policies [Abstract]

Estimated useful lives of property, plant and equipment

Property, plant and equipment are stated at cost. Depreciation is computed using the straight-line method over the following estimated useful lives:

Buildings	31-39 years
Building improvements	10-39 years
Furniture and equipment	3-15 years
Software	Lesser of 3-5 years or product life
Leasehold improvements	Lesser of the asset life or lease term

Assumptions used in valuing stock options granted

	Year Ended December 31,
	2012			2011			2010
Expected dividend yield		0	%		0	%		0	%
Expected volatility		41-52	%		60	%		55	%
Risk-free interest rate		0.36-0.54	%		0.35-1.04	%		0.49-1.46	%
Expected average life of options	3.4 years			3.4 years			3.4 years

Fair value measurements (Tables)

12 Months Ended

Dec. 31, 2012

Fair value measurements [Abstract]

Fair Value Hierarchy for Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis

The following table represents the Company's fair value hierarchy for its financial assets and liabilities measured at fair value on a recurring basis:

	At December 31, 2012
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	42,720	$	-	$	-	$	42,720
Total assets		$	42,720	$	-	$	-	$	42,720


	At December 31, 2011
(in thousands)		Level 1		Level 2		Level 3		Total
Assets:
Investment in money market funds (1)		$	73,005	$	-	$	-	$	73,005
U.S. Treasury securities (2)			-		1,966		-		1,966
Total assets		$	73,005	$	1,966	$	-	$	74,971

Liabilities:
Contingent value rights		$	-	$	-	$	4,753	$	4,753
Total liabilities		$	-	$	-	$	4,753	$	4,753

(1) Included in cash and cash equivalents in accompanying consolidated balance sheets.

(2) Included in investments in accompanying consolidated balance sheets.

Reconciliation of Liabilities Measured at Fair Value Using Significant Unobservable Inputs (Level 3)

(in thousands)
Balance at January 1, 2011	$	14,532
Expense (income) included in earnings		221
Settlements		(10,000	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at December 31, 2011		4,753
Expense (income) included in earnings		(3,005	)
Settlements		(1,748	)
Purchases, sales and issuances		-
Transfers in/(out) of Level 3		-
Balance at December 31, 2012	$	-

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References + Details

Investments (Tables)

12 Months Ended

Dec. 31, 2012

Investments [Abstract]

Summary of Available-for-sale Securities

	At December 31, 2011
(in thousands)	Amortized Costs		Gross Unrealized Gains		Gross Unrealized Losses		Estimated Fair Market Value
U.S. Treasury securities	$	1,966	$	-	$	-	$	1,966

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62557-112803

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27337-111563

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27198-111563

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 320
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6957658&loc=d3e62586-112803

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27161-111563

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27357-111563

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6872113&loc=d3e27290-111563

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 19, 20, 21
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 17
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 03-1
-Paragraph 21
-Subparagraph a, b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Accounts receivable (Tables)

12 Months Ended

Dec. 31, 2012

Accounts receivable [Abstract]

Accounts receivable

Accounts receivable consist of the following:

	December 31,
(in thousands)	2012		2011
Billed	$	76,155	$	55,188
Unbilled		19,888		18,965
Total	$	96,043	$	74,153

Inventories (Tables)

12 Months Ended

Dec. 31, 2012

Inventories [Abstract]

Inventories

Inventories consist of the following:

	December 31,
(in thousands)	2012		2011
Raw materials and supplies	$	2,733	$	2,313
Work-in-process		9,813		10,149
Finished goods		2,615		2,199
Total inventories	$	15,161	$	14,661

Property, plant and equipment (Tables)

12 Months Ended

Dec. 31, 2012

Property, plant and equipment [Abstract]

Property, plant and equipment

Property, plant and equipment consist of the following:

	December 31,
(in thousands)	2012			2011
Land and improvements	$	4,839		$	4,115
Buildings, building improvements and leasehold improvements		66,953			26,122
Furniture and equipment		91,772			42,135
Software		15,691			11,854
Construction-in-progress		105,452			157,206
		284,707			241,432
Less: Accumulated depreciation and amortization		(42,943	)		(32,459	)
Total Property, plant and equipment, net	$	241,764		$	208,973

Long-term debt (Tables)

12 Months Ended

Dec. 31, 2012

Long-term debt [Abstract]

Components of long-term indebtedness

The components of long-term indebtedness are as follows:

	December 31,
(in thousands)	2012			2011
Construction loan dated July 2011; one month LIBOR plus 3%, due July 2017	$	29,375		$	26,095
Equipment loan dated August 2011; one month LIBOR plus 3%, due December 2017		11,068			1,426
Term loan dated December 2009; three month LIBOR plus 3.25%, due December 2014		18,200			19,717
Term loan dated November 2009; three month LIBOR plus 3.25%, due November 2014		4,131			4,478
Loan dated October 2004; 3.0%, repaid in March 2012		-			2,500
Term loan dated October 2004; 3.48%, repaid in March 2012		-			5,238
Total long-term indebtedness		62,774			59,454
Less current portion of long-term indebtedness		(4,470	)		(5,360	)
Noncurrent portion of long-term indebtedness	$	58,304		$	54,094

Schedule of Maturities of Long-term Debt [Table Text Block]

Scheduled principal repayments and maturities on long-term debt as of December 31, 2012 are as follows:

(in thousands)
2013	$	4,470
2014		23,075
2015		2,607
2016		2,607
2017		30,015
	$	62,774

Stockholders' equity (Tables)

12 Months Ended

Dec. 31, 2012

Stockholders' equity [Abstract]

Option award activity

The following is a summary of option award activity under the Emergent Plans:

	2006 Plan					2004 Plan
	Number of Shares			Weighted-Average Exercise Price		Number of Shares		Weighted-Average Exercise Price		Aggregate Intrinsic Value
Outstanding at December 31, 2011		3,090,909		$	17.35		53,156	$	8.86	$	6,238,427
Exercisable at December 31, 2011		1,459,049		$	14.19		53,156	$	8.86	$	5,650,832
Granted		785,941			15.65		-		-
Exercised		(89,125	)		8.53		-		-
Forfeited		(221,328	)		19.24		-		-
Outstanding at December 31, 2012		3,566,397		$	17.08		53,156	$	8.86	$	4,802,547
Exercisable at December 31, 2012		2,151,700		$	16.26		53,156	$	8.86	$	4,477,056
Options expected to vest at December 31, 2012		1,056,036		$	18.15		-	$	-	$	245,395

Restricted stock units activity

The following is a summary of restricted stock unit award activity under the 2006 Plan:

	Number of Shares			Weighted-Average Grant Price		Aggregate Intrinsic Value
Outstanding at December 31, 2011		635,500		$	20.89	$	10,714,450
Granted		413,022			15.61
Vested		(260,738	)		15.22
Forfeited		(67,716	)		19.36
Outstanding at December 31, 2012		720,068		$	20.89	$	11,549,891

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

Stock-based compensation expense was recorded in the following financial statement line items:

	December 31,
(in thousands)	2012		2011		2010
Cost of product sales	$	513	$	466	$	324
Research and development		3,451		3,203		1,635
Selling, general and administrative		7,151		7,070		5,104
Total stock-based compensation expense	$	11,115	$	10,739	$	7,063

- Definition

Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.

+ References + Details

Restructuring (Tables)

12 Months Ended

Dec. 31, 2012

Restructuring [Abstract]

Costs of the restructuring

The Company has completed this restructuring. The costs of the restructuring are detailed below:

	Incurred in		Inception to Date		Total
(in thousands)	2011		Costs Incurred		Incurred
Termination benefits	$	475	$	2,893	$	2,893
Contract termination costs		1,923		2,295		2,295
Other costs		90		350		350
Total	$	2,488	$	5,538	$	5,538

Summary of the activity for liabilities related to EPDU restructuring

The following is a summary of the activity for the liabilities related to the EPDU restructuring:

				Lease
	Termination			Termination
(in thousands)	Benefits			Costs			Total
Balance at December 31, 2010	$	2,418		$	650		$	3,068
Expenses incurred		475			1,923			2,398
Amount paid		(2,893	)		(2,295	)		(5,188	)
Other adjustments		-			(278	)		(278	)
Balance at December 31, 2011	$	-		$	-		$	-

Leases (Tables)

12 Months Ended

Dec. 31, 2012

Leases [Abstract]

Future Minimum Lease Payments under Operating Lease Obligations

Future minimum lease payments under operating lease obligations as of December 31, 2012 were as follows:

(in thousands)
2013	$	3,447
2014		3,497
2015		2,331
2016		1,377
2017		-
Total minimum lease payments	$	10,652

Earnings per share (Tables)

12 Months Ended

Dec. 31, 2012

Earnings per share [Abstract]

Summary of basic and diluted net income per share

The following table presents the calculation of basic and diluted net income (loss) per share:

	Year Ended December 31,
(in thousands, except share and per share data)	2012		2011		2010
Numerator:
Net income	$	23,524	$	23,019	$	51,698

Denominator:
Weighted-average number of shares—basic		36,080,495		35,658,907		31,782,286
Dilutive securities—equity awards		340,167		547,145		757,214
Weighted-average number of shares—diluted		36,420,662		36,206,052		32,539,500

Earnings per share-basic	$	0.65	$	0.65	$	1.63
Earnings per share-diluted	$	0.65	$	0.64	$	1.59

Segment information (Tables)

12 Months Ended

Dec. 31, 2012

Segment information [Abstract]

Segment information

	Reportable Segments
(in thousands)	Biodefense		Biosciences			All Other			Total
Year Ended December 31, 2012
External revenue	$	276,469	$	5,419		$	-		$	281,888
Intersegment revenue (expense)		-		-			-			-
Research and development		68,579		44,588			7,059			120,226
Interest revenue		-		-			134			134
Interest expense		-		-			(6	)		(6	)
Depreciation and amortization		8,951		2,147			99			11,197
Net income (loss)		94,865		(63,928	)		(7,413	)		23,524
In-process research and development assets		-		41,800			-			41,800
Goodwill		-		5,502			-			5,502
Total assets		354,010		56,148			154,072			564,230
Expenditures for long-lived assets		52,957		810			78			53,845
Year Ended December 31, 2011
External revenue	$	251,037	$	22,347		$	-		$	273,384
Intersegment revenue (expense)		-		-			-			-
Research and development		57,833		61,566			5,433			124,832
Interest revenue		-		-			105			105
Interest expense		-		-			-			-
Depreciation and amortization		6,213		3,070			72			9,355
Net income (loss)		86,836		(56,438	)		(7,379	)		23,019
In-process research and development assets		-		51,400			-			51,400
Goodwill		-		5,502			-			5,502
Total assets		290,302		92,321			164,241			546,864
Expenditures for long-lived assets		52,326		1,608			92			54,026
Year Ended December 31, 2010
External revenue	$	282,727	$	3,444		$	-		$	286,171
Intersegment revenue (expense)		-		-			-			-
Research and development		52,191		32,895			4,209			89,295
Interest revenue		-		-			832			832
Interest expense		-		-			-			-
Depreciation and amortization		4,584		1,333			73			5,990
Net income (loss)		113,249		(53,676	)		(7,875	)		51,698
In-process research and development assets		-		51,400			-			51,400
Goodwill		-		5,502			-			5,502
Total assets		216,529		99,754			184,036			500,319
Expenditures for long-lived assets		21,728		373			-			22,101

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details

Quarterly financial data (unaudited) (Tables)

12 Months Ended

Dec. 31, 2012

Quarterly financial data (unaudited) [Abstract]

Quarterly financial information

Quarterly financial information for the years ended December 31, 2012 and 2011 is presented in the following tables:

	Three months ended
(in thousands)	March 31,			June 30,		September 30,		December 31,
Fiscal year 2012
Revenue	$	50,311		$	70,379	$	66,592	$	94,606
Income (loss) from operations		(12,538	)		8,653		9,817		24,035
Net income (loss)		(6,829	)		7,632		6,617		16,104
Net income (loss) per share, basic		(0.19	)		0.21		0.18		0.45
Net income (loss) per share, diluted		(0.19	)		0.21		0.18		0.44
Fiscal year 2011
Revenue	$	18,533		$	88,141	$	58,762	$	107,948
Income (loss) from operations		(35,506	)		20,207		1,408		45,990
Net income (loss)		(21,397	)		14,210		1,549		28,657
Net income (loss) per share, basic		(0.61	)		0.40		0.04		0.80
Net income (loss) per share, diluted		(0.61	)		0.39		0.04		0.78

Income taxes (Tables)

12 Months Ended

Dec. 31, 2012

Income taxes [Abstract]

Components of the provision for income taxes attributable to operations

Significant components of the provision for income taxes attributable to operations consist of the following:

	Year ended December 31,
(in thousands)	2012			2011			2010
Current
Federal	$	11,481		$	(3,795	)	$	16,664
State		(1,045	)		(1,110	)		187
International		103			74			102
Total current		10,539			(4,831	)		16,953
Deferred
Federal		3,758			19,055			10,003
State		(375	)		1,606			(774	)
Total deferred		3,383			20,661			9,229
Total provision for income taxes	$	13,922		$	15,830		$	26,182

Net deferred tax asset

The Company's net deferred tax asset consists of the following:

	December 31,
(in thousands)	2012			2011
Net operating loss carryforward	$	26,102		$	28,621
Research and development carryforward		3,556			3,556
Stock compensation		5,289			3,666
Foreign deferrals		64,009			61,255
Deferred revenue		-			485
Other		9,005			9,596
Deferred tax asset		107,961			107,179
Fixed assets		(22,040	)		(21,760	)
Other		(6,158	)		(6,902	)
Deferred tax liability		(28,198	)		(28,662	)
Valuation allowance		(67,412	)		(62,783	)
Net deferred tax asset	$	12,351		$	15,734

Reconciliation of taxes determined by applying U.S. federal statutory rate to loss before provision for income taxes

The provision for income taxes differs from the amount of taxes determined by applying the U.S. federal statutory rate to loss before provision for income taxes as a result of the following:

	Year ended December 31,
(in thousands)	2012			2011			2010
US	$	52,391		$	66,756		$	111,775
International		(14,945	)		(27,907	)		(33,895	)
Earnings before taxes on income		37,446			38,849			77,880

Federal tax at statutory rates	$	13,106		$	13,597		$	27,258
State taxes, net of federal benefit		(2,079	)		46			666
Impact of foreign operations		(3,604	)		(2,371	)		(7,713	)
Change in valuation allowance		4,629			3,193			6,394
Effect of foreign rates		(22	)		(12	)		(30	)
Tax credits		(2,904	)		(1,405	)		(1,754	)
Other differences		139			556			398
Permanent differences		4,657			2,226			963
Provision for income taxes	$	13,922		$	15,830		$	26,182

Gross unrecognized tax benefits activity

The table below presents the gross unrecognized tax benefits activity for 2012, 2011 and 2010:

(in thousands)
Gross unrecognized tax benefits at January 1, 2010	$	260
Increases for tax positions for prior years		16
Decreases for tax positions for prior years		(175	)
Increases for tax positions for current year		849
Settlements		-
Lapse of statute of limitations		-
Gross unrecognized tax benefits at December 31, 2010		950
Increases for tax positions for prior years		167
Decreases for tax positions for prior years		(61	)
Increases for tax positions for current year		-
Settlements		-
Lapse of statute of limitations		-
Gross unrecognized tax benefits at December 31, 2011		1,056
Increases for tax positions for prior years		25
Decreases for tax positions for prior years		(65	)
Increases for tax positions for current year		-
Settlements		-
Lapse of statute of limitations		-
Gross unrecognized tax benefits at December 31, 2012	$	1,016

Nature of the business and organization (Details)	Dec. 31, 2012 a
Nature of the business and organization [Abstract]
Area of land in Lansing, Michigan (in acres)	12.5

Summary of significant accounting policies (Details)	12 Months Ended
Summary of significant accounting policies (Details)	Dec. 31, 2012 USD ($) shares	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)
Restricted Cash [Abstract]
Restricted Cash	$ 220,000
Accounts, Notes, Loans and Financing Receivable [Line Items]
Unbilled accounts receivable	$ 96,043,000	$ 74,153,000
Property, Plant and Equipment [Line Items]
Number of doses of BioThrax to be supplied under contract	44,750,000
Period of contractual agreement	5 years
Percentage of total spending in collaboration used to determine the receivable, revenue, payable and expense during period (in hundredths)	50.00%
Capitalized interest [Abstract]
Interest costs incurred	$ 2,200,000	1,700,000	$ 1,800,000
Interest costs capitalized	$ 2,200,000	$ 1,700,000	$ 1,800,000
Assumptions used in valuing the stock options granted [Abstract]
Expected dividend yield (in hundredths)	0.00%	0.00%	0.00%
Expected volatility (in hundredths)		60.00%	55.00%
Risk-free interest rate, minimum (in hundredths)	0.36%	0.35%	0.49%
Risk-free interest rate, maximum (in hundredths)	0.54%	1.04%	1.46%
Minimum [Member]
Assumptions used in valuing the stock options granted [Abstract]
Expected volatility (in hundredths)	41.00%
Maximum [Member]
Assumptions used in valuing the stock options granted [Abstract]
Expected volatility (in hundredths)	52.00%
Buildings [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	31 years
Buildings [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	39 years
Building Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Building Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	39 years
Furniture and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Furniture and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	15 years
Software [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	Lesser of 3-5 years or product life
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Estimated useful lives	Lesser of the asset life or lease term
2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock unit conversion ratio	1.86
2006 Plan [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized for issuance under the plan (in shares) \| shares	11,178,826
Common stock available for future awards (in shares) \| shares	3,752,260
Contractual life of awards	10 years
Assumptions used in valuing the stock options granted [Abstract]
Expected average life of options	3 years 4 months 24 days	3 years 4 months 24 days	3 years 4 months 24 days
2006 Plan [Member] \| Minimum [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of option as percentage of fair market value at grant date, minimum (in hundredths)	100.00%
2006 Plan [Member] \| Maximum [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares that may be granted per year to a single participant (in shares) \| shares	287,700
Exercise period of options, maximum	10 years
Emergent Plans [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock based employee compensation plans	2
Revenues [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk percentage (in hundredths)	97.90%	91.30%	97.50%
Accounts Receivable [Member] \| Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Concentration risk percentage (in hundredths)	99.90%	90.00%
Unbilled [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Unbilled accounts receivable	$ 19,888,000	$ 18,965,000

Fair value measurements (Details) - USD ($) $ in Thousands	12 Months Ended
Fair value measurements (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Unobservable Input Reconciliation [Roll Forward]
Balance beginning of period	$ 4,753	$ 14,532
Expense (income) included in earnings	(3,005)	221
Settlements	(1,748)	(10,000)
Purchases, sales and issuances	0	0
Transfers in/(out) of Level 3	0	0
Balance End of period	0	4,753
Long-term indebtedness [Abstract]
Total long-term indebtedness	62,774	59,454
Fair value of long-term indebtedness	62,800	59,500
Fair Value, Measurements, Recurring [Member]
Assets:
Investment in money market funds	42,720	73,005
U.S. Treasury securities		1,966
Total assets	42,720	74,971
Liabilities:
Contingent value rights		4,753
Total liabilities		4,753
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 1 [Member]
Assets:
Investment in money market funds	42,720	73,005
U.S. Treasury securities		0
Total assets	42,720	73,005
Liabilities:
Contingent value rights		0
Total liabilities		0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 2 [Member]
Assets:
Investment in money market funds	0	0
U.S. Treasury securities		1,966
Total assets	0	1,966
Liabilities:
Contingent value rights		0
Total liabilities		0
Fair Value, Measurements, Recurring [Member] \| Fair Value, Inputs, Level 3 [Member]
Assets:
Investment in money market funds	0	0
U.S. Treasury securities		0
Total assets	$ 0	0
Liabilities:
Contingent value rights		4,753
Total liabilities		$ 4,753

Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Schedule of Available-for-sale Securities [Line Items]
Estimated Fair Market Value	$ 0	$ 1,966
U.S. Treasury securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Costs	1,966
Gross Unrealized Gains	0
Gross Unrealized Losses	0
Estimated Fair Market Value	$ 1,966

- Definition

Total of debt securities categorized neither as held-to-maturity nor trading which are intended be sold or mature within one year from the balance sheet date or the normal operating cycle, whichever is longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 25
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=7534914&loc=d3e22054-111558

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 320
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6871852&loc=d3e26626-111562

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher AICPA
-Name Accounting Research Bulletin (ARB)
-Number 43
-Section A
-Paragraph 4, 5
-Chapter 3
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15D
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 13, 17
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 16
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15E
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 115
-Paragraph 12
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 22
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name FASB Staff Position (FSP)
-Number FAS115-1/124-1
-Paragraph 15C
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

+ Details

Accounts receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 96,043	$ 74,153
Billed [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	76,155	55,188
Unbilled [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable	$ 19,888	$ 18,965

Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Inventories [Abstract]
Raw materials and supplies	$ 2,733	$ 2,313
Work-in-process	9,813	10,149
Finished goods	2,615	2,199
Total inventories	$ 15,161	$ 14,661

Property, plant and equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 284,707	$ 241,432
Less: Accumulated depreciation and amortization	(42,943)	(32,459)
Total Property, plant and equipment, net	241,764	208,973
Depreciation and amortization expense	11,197	9,355	$ 5,990
Land and improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	4,839	4,115
Buildings, building improvements and leasehold improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	66,953	26,122
Furniture and equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	91,772	42,135
Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	15,691	11,854
Construction-in-progress [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment	$ 105,452	$ 157,206

In-process research and development and goodwill (Details) $ in Millions	12 Months Ended
	Dec. 31, 2012 USD ($)
In-process research and development and goodwill [Abstract]
Impairment of IPR&D assets	$ 9.6

Assets held for sale (Details) $ in Thousands	12 Months Ended
Assets held for sale (Details) $ in Thousands	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)
Assets held for sale [Abstract]
Sales price of asset held for sale	$ 12,200
Long Lived Assets Held-for-sale [Line Items]
Number of buildings held for sale	2
Impairment charges for assets held for sale	$ 0	$ 976	$ 1,218

Long-term debt (Details)	12 Months Ended
Long-term debt (Details)	Dec. 31, 2012 USD ($) ft²	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)
Long-Term Debt [Line Items]
Total long-term indebtedness	$ 62,774,000	$ 59,454,000
Less current portion of long-term indebtedness	(4,470,000)	(5,360,000)
Noncurrent portion of long-term indebtedness	$ 58,304,000	54,094,000
Loan advance expiration date	Jul. 01, 2012
Cash portion of the acquisition of the development and manufacturing facility	$ 53,845,000	54,026,000	$ 22,101,000
Long-term Debt, Fiscal Year Maturity [Abstract]
2013	4,470,000
2014	23,075,000
2015	2,607,000
2016	2,607,000
2017	30,015,000
Long-term Debt, Total	62,774,000	$ 59,454,000
PNC Bank [Member]
Long-Term Debt [Line Items]
Debt covenant, minimum cash and liquid investments balance	$ 50,000,000
Debt covenant, leverage ratio, maximum	2.0
Debt covenant, debt coverage ratio	1.25
Number of quarters used in calculating debt covenant ratios	4
Debt covenant compliance	20121231	20111231
HSBC Bank [Member]
Long-Term Debt [Line Items]
Debt covenant, leverage ratio, maximum	1.00
Debt covenant, debt coverage ratio	1.25
Number of quarters used in calculating debt covenant ratios	4
Debt covenant compliance	20121231	20111231
Construction Loan [Member]
Long-Term Debt [Line Items]
Total long-term indebtedness	$ 29,375,000	$ 26,095,000
Maturity date	Jul. 01, 2017
Description of variable rate basis	one month LIBOR plus
Interest rate, stated percentage (in hundredths)	3.00%
Maximum borrowing capacity	$ 30,000,000
Debt Instrument, Periodic Payment, Principal	125,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total	$ 29,375,000	26,095,000
Construction Loan [Member] \| PNC Bank [Member]
Long-Term Debt [Line Items]
Effective interest rate at period end (in hundredths)	3.21%
Equipment Loan [Member]
Long-Term Debt [Line Items]
Total long-term indebtedness	$ 11,068,000	1,426,000
Maturity date	Dec. 01, 2017
Description of variable rate basis	one month LIBOR plus
Interest rate, stated percentage (in hundredths)	3.00%
Maximum borrowing capacity	$ 12,000,000
Loan advance expiration date	Dec. 01, 2012
Debt Instrument, Periodic Payment, Principal	$ 92,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total	$ 11,068,000	1,426,000
Equipment Loan [Member] \| PNC Bank [Member]
Long-Term Debt [Line Items]
Effective interest rate at period end (in hundredths)	3.21%
Term Loan December 2009 [Member]
Long-Term Debt [Line Items]
Total long-term indebtedness	$ 18,200,000	19,717,000
Maturity date	Dec. 01, 2014
Description of variable rate basis	three month LIBOR plus
Interest rate, stated percentage (in hundredths)	3.25%
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total	$ 18,200,000	19,717,000
Term Loan December 2009 [Member] \| HSBC Bank [Member]
Long-Term Debt [Line Items]
Debt Instrument, Periodic Payment, Principal	126,000
Face amount of debt instrument	$ 22,800,000
Effective interest rate at period end (in hundredths)	3.56%
Term Loan November 2009 repaid July 2011 [Member] \| HSBC Bank [Member]
Long-Term Debt [Line Items]
Face amount of debt instrument	$ 7,000,000
Facility acquired	8,200,000
Cash portion of the acquisition of the development and manufacturing facility	1,200,000
Term Loan November 2009 [Member]
Long-Term Debt [Line Items]
Total long-term indebtedness	$ 4,131,000	4,478,000
Maturity date	Nov. 01, 2014
Description of variable rate basis	three month LIBOR plus
Interest rate, stated percentage (in hundredths)	3.25%
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total	$ 4,131,000	4,478,000
Term Loan November 2009 [Member] \| HSBC Bank [Member]
Long-Term Debt [Line Items]
Debt Instrument, Periodic Payment, Principal	$ 29,000
Effective interest rate at period end (in hundredths)	3.56%
Facility acquired	$ 6,400,000
Cash portion of the acquisition of the development and manufacturing facility	1,200,000
Term loan April 2006 [Member] \| HSBC Bank [Member]
Long-Term Debt [Line Items]
Face amount of debt instrument	8,500,000
Facility acquired	9,800,000
Cash portion of the acquisition of the development and manufacturing facility	$ 1,300,000
Area of facility acquired (in square feet) \| ft²	145,000
Loan Dated October 2004 [Member]
Long-Term Debt [Line Items]
Total long-term indebtedness	$ 0	2,500,000
Maturity date	Mar. 01, 2012
Interest rate, stated percentage (in hundredths)	3.00%
Face amount of debt instrument	$ 2,500,000
Letter of credit	1,300,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total	0	2,500,000
Term Loan October 2004 [Member]
Long-Term Debt [Line Items]
Total long-term indebtedness	$ 0	5,238,000
Maturity date	Mar. 01, 2012
Interest rate, stated percentage (in hundredths)	3.48%
Face amount of debt instrument	$ 7,000,000
Long-term Debt, Fiscal Year Maturity [Abstract]
Long-term Debt, Total	$ 0	$ 5,238,000

Stockholders' equity (Details) - USD ($)	12 Months Ended
Stockholders' equity (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Preferred stock
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, voting rights	1
Treasury Stock [Abstract]
Stock Repurchase Program, Authorized Amount	$ 35,000,000
Stock repurchased during period, value	(5,906,000)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expense	$ 11,115,000	$ 10,739,000	$ 7,063,000
Aggregate intrinsic value [Abstract]
Weighted average remaining contractual term of options outstanding	4 years 2 months 12 days	4 years 10 months 24 days
Weighted average remaining contractual term of options exercisable	3 years 6 months	4 years 1 month 6 days
Weighted average grant date fair value of options granted (in dollars per share)	$ 5.16	$ 10.09	$ 6.48
Total intrinsic value of options exercised	$ 589,000	$ 10,200,000	$ 7,500,000
Total fair value of awards vested	10,300,000	7,900,000	5,800,000
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 11,115,000	10,739,000	7,063,000
Chief Executive Officer [Member]
Treasury Stock [Abstract]
Stock repurchased as part of stock swap (in shares)	4,677
Stock repurchased as part of stock swap, value	$ 74,000
Stock Options [Member]
Aggregate Intrinsic Value [Abstract]
Outstanding, beginning of period	6,238,427
Exercisable, beginning of period	5,650,832
Outstanding, end of period	4,802,547	6,238,427
Exercisable, end of period	4,477,056	$ 5,650,832
Options expected to vest, end of period	$ 245,395
Restricted Stock Units (RSUs) [Member]
Restricted stock unit award activity [Roll Forward]
Outstanding, beginning of period (in shares)	635,500
Granted (in shares)	413,022
Vested (in shares)	(260,738)
Forfeited (in shares)	(67,716)
Outstanding, end of period (in shares)	720,068	635,500
Weighted-Average Grant Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 20.89
Granted (in dollars per share)	15.61
Vested (in dollars per share)	15.22
Forfeited (in dollars per share)	19.36
Outstanding, end of period (in dollars per share)	$ 20.89	$ 20.89
Aggregate intrinsic value [Abstract]
Outstanding, beginning of period	$ 10,714,450
Outstanding, end of period	$ 11,549,891	$ 10,714,450
Stock Repurchase Plan of 2012 [Member]
Treasury Stock [Abstract]
Stock repurchased during period (in shares)	398,481
Stock repurchased during period, value	$ 5,800,000
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	513,000	466,000	324,000
Research and Development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	3,451,000	3,203,000	1,635,000
General and Administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 7,151,000	$ 7,070,000	$ 5,104,000
2006 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted stock unit conversion ratio	1.86
2006 Plan [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized for issuance under the plan (in shares)	11,178,826
Common stock available for future awards (in shares)	3,752,260
Contractual life of awards	10 years
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	3,090,909
Exercisable, beginning of period (in shares)	1,459,049
Granted (in shares)	785,941
Exercised (in shares)	(89,125)
Forfeited (in shares)	(221,328)
Outstanding, end of period (in shares)	3,566,397	3,090,909
Exercisable, end of period (in shares)	2,151,700	1,459,049
Options expected to vest, end of period (in shares)	1,056,036
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 17.35
Exercisable, beginning of period (in dollars per share)	14.19
Granted (in dollars per share)	15.65
Exercised (in dollars per share)	8.53
Forfeited (in dollars per share)	19.24
Outstanding, end of period (in dollars per share)	17.08	$ 17.35
Exercisable, end of period (in dollars per share)	16.26	$ 14.19
Options expected to vest, end of period (in dollars per share)	$ 18.15
2006 Plan [Member] \| Stock Options [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price of option as percentage of fair market value at grant date, minimum (in hundredths)	100.00%
2006 Plan [Member] \| Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum number of shares that may be granted per year to a single participant (in shares)	287,700
Exercise period of options, maximum	10 years
2004 Plan [Member] \| Stock Options [Member]
Options outstanding [Roll Forward]
Outstanding, beginning of period (in shares)	53,156
Exercisable, beginning of period (in shares)	53,156
Granted (in shares)	0
Exercised (in shares)	0
Forfeited (in shares)	0
Outstanding, end of period (in shares)	53,156	53,156
Exercisable, end of period (in shares)	53,156	53,156
Options expected to vest, end of period (in shares)	0
Weighted-Average Exercise Price [Roll Forward]
Outstanding, beginning of period (in dollars per share)	$ 8.86
Exercisable, beginning of period (in dollars per share)	8.86
Granted (in dollars per share)	0
Exercised (in dollars per share)	0
Forfeited (in dollars per share)	0
Outstanding, end of period (in dollars per share)	8.86	$ 8.86
Exercisable, end of period (in dollars per share)	8.86	$ 8.86
Options expected to vest, end of period (in dollars per share)	$ 0
Emergent Plans [Member] \| Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock based employee compensation plans	2
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock authorized for issuance under the plan (in shares)	1,000,000
Discount from Market Price, Offering Date	15.00%
Maximum number of shares that may be granted per year to a single participant (in shares)	800
Stock-based compensation expense	$ 11,000
Employee Stock Purchase Plan [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Subscription Rate	1.00%
Employee Stock Purchase Plan [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Subscription Rate	10.00%

Variable interest entities (Details) - Oxford-Emergent Tuberculosis Consortium [Member] - USD ($)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011
Variable Interest Entity [Line Items]
Equity interest in variable interest entity (in hundredths)	51.00%
Assets of variable interest entities included in consolidated balance sheet	$ 2,000,000	$ 461,000
Liabilities of variable interest entities included in consolidated balance sheet	2,000,000	947,000
Net loss	10,700,000	13,200,000
Net losses of variable interest entities included in consolidated statement of operations	$ 5,400,000	$ 6,700,000

Collaboration Agreements (Details) - USD ($)	12 Months Ended
Collaboration Agreements (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Collaborative arrangements [Line Items]
Contracts and grants revenue	$ 66,009,000	$ 70,975,000	$ 34,790,000
Abbott Laboratories TRU016 [Member]
Collaborative arrangements [Line Items]
Contracts and grants revenue	2,700,000	17,700,000	1,200,000
Recognition of deferred revenue	1,400,000	10,500,000	831,000
Revenue related to achievement of a development milestone		6,000,000
Revenues related to collaborative research funding	1,400,000	1,200,000	398,000
Net receivable from collaboration agreements		6,800,000
Pfizer CD20 [Member]
Collaborative arrangements [Line Items]
Contracts and grants revenue	1,200,000	1,900,000	992,000
Recognition of deferred revenue	68,000	52,000	9,000
Revenues related to collaborative research funding	1,100,000	1,800,000	$ 983,000
Net receivable from collaboration agreements	$ 52,000	$ 302,000

Restructuring (Details) - USD ($) $ in Thousands	12 Months Ended
Restructuring (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011
Summary of activity for liabilities [Roll Forward]
Expenses incurred	$ 3,100	$ 2,500
Restructuring expenses	3,100	2,500
EPDU Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred in 2011		2,488
Inception to date costs incurred	5,538
Total incurred	5,538
Summary of activity for liabilities [Roll Forward]
Beginning balance	0	3,068
Expenses incurred		2,398
Amount paid		(5,188)
Other adjustments		(278)
Ending balance		0
Restructuring expenses		2,398
Termination benefits [Member] \| EPDU Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred in 2011		475
Inception to date costs incurred	2,893
Total incurred	2,893
Summary of activity for liabilities [Roll Forward]
Beginning balance	0	2,418
Expenses incurred		475
Amount paid		(2,893)
Other adjustments		0
Ending balance		0
Restructuring expenses		475
Contract termination costs [Member] \| EPDU Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred in 2011		1,923
Inception to date costs incurred	2,295
Total incurred	2,295
Summary of activity for liabilities [Roll Forward]
Beginning balance	0	650
Expenses incurred		1,923
Amount paid		(2,295)
Other adjustments		(278)
Ending balance		0
Restructuring expenses		1,923
Other costs [Member] \| EPDU Restructuring Plan [Member]
Restructuring Cost and Reserve [Line Items]
Incurred in 2011		$ 90
Inception to date costs incurred	350
Total incurred	$ 350

Leases (Details) - USD ($) $ in Thousands	12 Months Ended
Leases (Details) - USD ($) $ in Thousands	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Operating Leased Assets [Line Items]
Total lease expense	$ 3,600	$ 3,800	$ 2,600
Future minimum lease payments under operating lease
2013	3,447
2014	3,497
2015	2,331
2016	1,377
2017 and beyond	0
Total minimum lease payments	$ 10,652
Office space - England [Member]
Operating Leased Assets [Line Items]
Operating lease expiration date	Nov. 01, 2016
Office and laboratory space - Germany [Member]
Operating Leased Assets [Line Items]
Operating lease expiration date	Jun. 01, 2015
Office and laboratory space - Washington [Member]
Operating Leased Assets [Line Items]
Operating lease expiration date	Apr. 01, 2015
Office and laboratory space - Maryland [Member]
Operating Leased Assets [Line Items]
Operating lease expiration date	Dec. 01, 2016
Annual escalation percentage (in hundredths)	3.00%
Term of renewal option	5 years

Business Interruption Insurance Recovery (Details) $ in Millions	12 Months Ended
	Dec. 31, 2012 USD ($)
Business Interruption Insurance Recovery [Abstract]
BusinessInterruptionInsuranceRevenue	$ 1.7

Related party transactions (Details) - USD ($)	12 Months Ended
Related party transactions (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Saudi Arabia [Member]
Related Party Transaction [Line Items]
Percentage of net sales of biodefense products subject to payment to related party (in hundredths)	17.50%
United Arab Emirates [Member]
Related Party Transaction [Line Items]
Percentage of net sales of biodefense products subject to payment to related party (in hundredths)	15.00%
Family Members of Executive Chairman [Member]
Related Party Transaction [Line Items]
Costs incurred from services rendered under marketing/consulting agreement		$ 35,000	$ 25,000
Member of Board of Directors [Member]
Related Party Transaction [Line Items]
Costs incurred from services rendered under marketing/consulting agreement		$ 225,000	$ 180,000

Earnings per share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Numerator:
Net income	$ 16,104	$ 6,617	$ 7,632	$ (6,829)	$ 28,657	$ 1,549	$ 14,210	$ (21,397)	$ 23,524	$ 23,019	$ 51,698
Denominator:
Weighted-average number of shares-basic (in shares)									36,080,495	35,658,907	31,782,286
Dilutive securities-equity awards (in shares)									340,167	547,145	757,214
Weighted-average number of shares-diluted (in shares)									36,420,662	36,206,052	32,539,500
Earnings per share-basic (in dollars per share)	$ 0.45	$ 0.18	$ 0.21	$ (0.19)	$ 0.80	$ 0.04	$ 0.40	$ (0.61)	$ 0.65	$ 0.65	$ 1.63
Earnings per share-diluted (in dollars per share)	$ 0.44	$ 0.18	$ 0.21	$ (0.19)	$ 0.78	$ 0.04	$ 0.39	$ (0.61)	$ 0.65	$ 0.64	$ 1.59
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive shares excluded from calculation (in shares)									2,900,000	746,000	1,400,000

Segment information (Details) $ in Thousands	3 Months Ended								12 Months Ended
Segment information (Details) $ in Thousands	Dec. 31, 2012 USD ($)	Sep. 30, 2012 USD ($)	Jun. 30, 2012 USD ($)	Mar. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Sep. 30, 2011 USD ($)	Jun. 30, 2011 USD ($)	Mar. 31, 2011 USD ($)	Dec. 31, 2012 USD ($)	Dec. 31, 2011 USD ($)	Dec. 31, 2010 USD ($)
Segment Reporting Information [Line Items]
Number of business segments									2
Number of business units									2
External revenue									$ 281,888	$ 273,384	$ 286,171
Intersegment revenue (expense)									0	0	0
Research and development									120,226	124,832	89,295
Interest revenue									134	105	832
Interest expense									(6)	0	0
Depreciation and amortization									11,197	9,355	5,990
Net income (loss)	$ 16,104	$ 6,617	$ 7,632	$ (6,829)	$ 28,657	$ 1,549	$ 14,210	$ (21,397)	23,524	23,019	51,698
In-process research and development assets	41,800				51,400				41,800	51,400	51,400
Goodwill	5,502				5,502				5,502	5,502	5,502
Total assets	564,230				546,864				564,230	546,864	500,319
Expenditures for long-lived assets									53,845	54,026	22,101
Biodefense [Member]
Segment Reporting Information [Line Items]
External revenue									276,469	251,037	282,727
Intersegment revenue (expense)									0	0	0
Research and development									68,579	57,833	52,191
Interest revenue									0	0	0
Interest expense									0	0	0
Depreciation and amortization									8,951	6,213	4,584
Net income (loss)									94,865	86,836	113,249
In-process research and development assets	0				0				0	0	0
Goodwill	0				0				0	0	0
Total assets	354,010				290,302				354,010	290,302	216,529
Expenditures for long-lived assets									52,957	52,326	21,728
Biosciences [Member]
Segment Reporting Information [Line Items]
External revenue									5,419	22,347	3,444
Intersegment revenue (expense)									0	0	0
Research and development									44,588	61,566	32,895
Interest revenue									0	0	0
Interest expense									0	0	0
Depreciation and amortization									2,147	3,070	1,333
Net income (loss)									(63,928)	(56,438)	(53,676)
In-process research and development assets	41,800				51,400				41,800	51,400	51,400
Goodwill	5,502				5,502				5,502	5,502	5,502
Total assets	56,148				92,321				56,148	92,321	99,754
Expenditures for long-lived assets									810	1,608	373
All Other [Member]
Segment Reporting Information [Line Items]
External revenue											0
Intersegment revenue (expense)									0	0	0
Research and development									7,059	5,433	4,209
Interest revenue									134	105	832
Interest expense									(6)	0	0
Depreciation and amortization									99	72	73
Net income (loss)									(7,413)	(7,379)	(7,875)
In-process research and development assets	0				0				0	0	0
Goodwill	0				0				0	0	0
Total assets	$ 154,072				$ 164,241				154,072	164,241	184,036
Expenditures for long-lived assets									$ 78	$ 92	$ 0

Quarterly financial data (unaudited) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2012	Mar. 31, 2012	Dec. 31, 2011	Sep. 30, 2011	Jun. 30, 2011	Mar. 31, 2011	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Quarterly financial data (unaudited) [Abstract]
Revenue	$ 94,606	$ 66,592	$ 70,379	$ 50,311	$ 107,948	$ 58,762	$ 88,141	$ 18,533	$ 281,888	$ 273,384	$ 286,171
Income (loss) from operations	24,035	9,817	8,653	(12,538)	45,990	1,408	20,207	(35,506)	29,967	32,099	73,557
Net income (loss)	$ 16,104	$ 6,617	$ 7,632	$ (6,829)	$ 28,657	$ 1,549	$ 14,210	$ (21,397)	$ 23,524	$ 23,019	$ 51,698
Net income (loss) per share, basic (in dollars per share)	$ 0.45	$ 0.18	$ 0.21	$ (0.19)	$ 0.80	$ 0.04	$ 0.40	$ (0.61)	$ 0.65	$ 0.65	$ 1.63
Net income (loss) per share, diluted (in dollars per share)	$ 0.44	$ 0.18	$ 0.21	$ (0.19)	$ 0.78	$ 0.04	$ 0.39	$ (0.61)	$ 0.65	$ 0.64	$ 1.59

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.21)
-URI http://asc.fasb.org/extlink&oid=6880815&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=16381557&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=7655603&loc=d3e1252-109256

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04.19)
-URI http://asc.fasb.org/extlink&oid=6879464&loc=d3e573970-122913

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.23)
-URI http://asc.fasb.org/extlink&oid=6879574&loc=d3e536633-122882

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 18
-Article 7

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 128
-Paragraph 36, 37, 38
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Emerging Issues Task Force (EITF)
-Number 07-4
-Paragraph 4
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 03
-Paragraph 20
-Article 5

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 04
-Paragraph 21
-Article 9

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

Income taxes (Details) - USD ($)	12 Months Ended
Income taxes (Details) - USD ($)	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Current
Federal	$ 11,481,000	$ (3,795,000)	$ 16,664,000
State	(1,045,000)	(1,110,000)	187,000
International	103,000	74,000	102,000
Total current	10,539,000	(4,831,000)	16,953,000
Deferred
Federal	3,758,000	19,055,000	10,003,000
State	(375,000)	1,606,000	(774,000)
Total deferred	3,383,000	20,661,000	9,229,000
Total provision for income taxes	13,922,000	15,830,000	26,182,000
Net deferred tax asset [Abstract]
Net operating loss carryforward	26,102,000	28,621,000
Research and development carryforward	3,556,000	3,556,000
Stock compensation	5,289,000	3,666,000
Foreign deferred tax assets	64,009,000	61,255,000
Deferred revenue	0	485,000
Other	9,005,000	9,596,000
Deferred tax asset	107,961,000	107,179,000
Fixed assets	(22,040,000)	(21,760,000)
Other	(6,158,000)	(6,902,000)
Deferred tax liability	(28,198,000)	(28,662,000)
Valuation allowance	(67,412,000)	(62,783,000)
Net deferred tax asset	12,351,000	15,734,000
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 43,900,000
Period of change in the nature or conduct of business following change in ownership	3 years
Income tax reconciliation [Abstract]
US	$ 52,391,000	66,756,000	111,775,000
International	(14,945,000)	(27,907,000)	(33,895,000)
Income (Loss), Including Portion Attributable to Noncontrolling Interest	37,446,000	38,849,000	77,880,000
Federal tax at statutory rates	13,106,000	13,597,000	27,258,000
State taxes, net of federal benefit	(2,079,000)	46,000	666,000
Impact of foreign operations	(3,604,000)	(2,371,000)	(7,713,000)
Change in valuation allowance	4,629,000	3,193,000	6,394,000
Effect of foreign rates	(22,000)	(12,000)	(30,000)
Tax credits	(2,904,000)	(1,405,000)	(1,754,000)
Other differences	139,000	556,000	398,000
Permanent differences	4,657,000	2,226,000	963,000
Total provision for income taxes	$ 13,922,000	$ 15,830,000	$ 26,182,000
Effective annual tax rate (in hundredths)	37.00%	41.00%	34.00%
Research and Development Tax Credit [Member]
Tax Credit Carryforward [Line Items]
Tax credit carryforward, amount	$ 3,600,000
Tax credit carryforwards, expiration date	Dec. 31, 2023
Cash flow presentation of the excess tax benefit attributable to exercise of stock options and restricted stock units [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Quantifying Misstatement in Current Year Financial Statements, Amount		$ 2,400,000	$ 909,000
U.S. Federal Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards, expiration year	2026
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 200,500,000
Operating loss carryforwards, expiration year	2018
Foreign Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 223,300,000

Income taxes, Income Tax Contingency (Details) - USD ($)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Income Tax Contingency [Line Items]
Accrued interest and penalties related to unrecognized tax benefits	$ 25,000	$ 26,000
Unrecognized tax benefits, current	153,000	104,000
Unrecognized tax benefits, noncurrent	863,000	952,000
Estimated unrecognized tax benefits expected to be reversed within next twelve months	75,000	50,000
Gross unrecognized tax benefits activity [Roll Forward]
Gross unrecognized tax benefits, beginning balance	1,056,000	950,000	$ 260,000
Increases for tax positions for prior years	25,000	167,000	16,000
Decreases for tax positions for prior years	(65,000)	(61,000)	(175,000)
Increases for tax positions for current year	0	0	849,000
Settlements	0	0	0
Lapse of statue of limitations	0	0	0
Gross unrecognized tax benefits, ending balance	$ 1,016,000	$ 1,056,000	$ 950,000

401(k) savings plan (Details) - USD ($) $ in Millions	12 Months Ended
401(k) savings plan (Details) - USD ($) $ in Millions	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
401(k) savings plan [Abstract]
Matching of qualified deferrals by employer, maximum (in hundredths)	50.00%
Percentage of employee's gross salary subject to employer's matching contribution (in hundredths)	6.00%
Matching contributions made by employer	$ 1.9	$ 1.8	$ 1.3

Subsequent Events (Details) $ in Millions	12 Months Ended
Subsequent Events (Details) $ in Millions	Dec. 31, 2012 USD ($)
Subsequent Event [Line Items]
Building purchase price	$ 27.5
Restructuring, Expected Cost	$ 3.0